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Abstract 
WEI SUN: Develop Small Molecule Regulators of GTPase-activating Proteins of 
ADP-ribosylation Factors (ARFGAPs) 
(Under the direction of Qisheng Zhang) 
GTPase-activating proteins of ADP-ribosylation factors (ARFGAPs) play 
essential roles in cell growth and migration, tumor invasion and neuronal development. 
Increasing evidence also implicates that ARFGAPs are involved in cancer, Alzheimer’s 
disease, and autism. However, the precise mechanisms whereby ARFGAPs regulate 
different diseases are yet to be elucidated. Consequently, direct and efficient regulators of 
ARFGAPs are urgently needed. In this thesis, I describe our efforts in developing small 
molecule ARFGAP inhibitors. 
It has been reported that a small molecule, QS11, potentially inhibits multiple 
ARFGAPs and is able to activate the Wnt/β-catenin signaling pathway. However, the 
mechanism of how QS11 inhibits different ARFGAPs is not well known. To define the 
molecular basis of the regulation of ARFGAP1 by QS11, we demonstrate that QS11 
binds to the lipid packing sensor (ALPS) motifs of ARFGAP1 instead of its GAP domain. 
This interaction also contributes to the inhibition of ARFGAP1 by QS11 (IC50 = 4.0 μM). 
Further studies suggest that QS11 inhibits ARFGAP1 activity in a non-competitive 
manner. Next, we have synthesized a small library of 31 analogs of QS11 to improve its 
potency and solubility. The binding affinities of these analogs to ARFGAP1 and their 
capacities to inhibit the GAP activity of ARFGAP1 are measured to establish a 
preliminary structure-activity relationship (SAR). 
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To identify novel small molecule inhibitors of the catalytic GAP domain of 
ARFGAPs, a fluorescence polarization-based ARFGAP assay has been developed. The Z’ 
factor of the assay is 0.75 in 384-well format. When applied to a pilot screen of the 
LOPAC library of 1,280 compounds, the assay demonstrated high reproducibility, 
reasonable hit rates, high tolerance with DMSO, and suitability for automation. 
Compared to the traditional assays for ARFGAP activity, this new assay is more user and 
environmentally friendly, and represents the first assay of ARFGAP enzymatic activity 
that allows the large-scale screening of compound libraries to identify inhibitors of 
ARFGAPs.  
The illustration of the mechanism by which QS11 interacts with ARFGAP1 also 
prompts us to engineer myristoylated ADP-ribosylation factor 1 (ARF1) for novel 
functions. Myristoylation is a pervasive co- and post-translational modification of 
proteins through the irreversible covalent bond formation with myristic acid at the N-
terminal glycine. Myristoylated proteins are involved in many signalling pathways, 
oncogenesis and viral replication. We have designed and synthesized six modified 
myristic acids and incorporated them into ARF1 through metabolic interference.  The 
resulting new ARF1 proteins can be loaded with GTP and the bound GTP is as efficiently 
hydrolyzed in the presence of ARFGAP1 as the native ARF1, but with the added  
potential functions of dye labeling, responding to redox changes or light illumiation, or 
selective separation. 
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Chapter 1.  
GTPase-activating Protein of ADP-ribosylation Factor (ARFGAP) 
 
1.1 Introduction to ARFGAP 
1.1.1 ARF family proteins  ARF family proteins are small GTPases that regulate 
membrane traffic and organelle structures.(1,2) They function through cycling between 
active GTP-bound forms and inactive GDP-bound forms (Fig. 1.1).(3) The activation of 
ARF-GDP is promoted by guanine nucleotide-exchange factors (GEFs) whereas the 
hydrolysis of ARF-GTP is catalyzed by GTPase-activating proteins (GAP). (1,4-6) 
Unlike other GTPases within the Ras super family, the nucleotide exchange rates and the 
intrinsic GTP hydrolysis rates for ARFs are slow. (7-10) Consequently, ARFGEFs and 
ARFGAPs are essential for the regulation of ARF activity.  
Figure 1.1. General regulation of ARF activation and inactivation. A GDP-bound, 
inactive form of ARF is converted to a GTP-bound, active form through GDP-GTP 
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exchange catalyzed by a GEF. The GTP molecule bound to ARF is then hydrolyzed to 
GDP with the aid of a GAP. 
Six conserved members of ARFs have been identified in mammalian cells. They 
are classified into three subfamilies based on structure similarities: Class I (ARF1, ARF2 
and ARF3), Class II (ARF4 and ARF5) and Class III (ARF6). ARFs localize both on the 
lipid membranes and in the cytosol.(11) ARF1 and ARF3 bind to the plasma membrane 
when in GTP-bound form and are released to cytosol when in GDP-bound form. ARF4, 
ARF5 and ARF6 bind to the plasma membrane when in either GTP- or GDP-bound 
form.(12,13) The N-terminal amphipathic helix of ARFs and the myristoylation at the N-
terminus are critical elements for their membrane binding (Fig. 1.2).(10,14) 
ARF1 and ARF6 have been extensively studied among the six ARFs. ARF1 
regulates vesicle trafficking from endoplasmic reticulum (ER) to Golgi, as well as 
function and morphology of Golgi.(15) ARF6 is involved in endocytosis, phagocytosis, 
receptor recycling and actin-cytoskeletal remodeling.(14,16) Importantly, overexpression 
of ARF6 has been found in multiple invasive breast cancer cells.(17-19) Knock-down of 
the level of ARF6 effectively reduced tumor invasion in these breast cancer cells. (17) 
Figure 1.2. The common hydrophobic area of the ARF family proteins. Cartoon 
representation of ARF1-GDP (left) and ARF1-GTP (center) are shown and compared.  
The switch regions are indicated in dark gray while the common hydrophobic area (CHA) 
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region in colors (switch 1 part, in blue; interswitch part, in green; switch 2 part, in red). A 
detailed view (right) of the CHA region is shown in ribbons, with the residues forming 
this region indicated in sticks. (This figure was reprinted from (4). Chavrier, P., and 
Ménétrey, J. (2010) Structure 18, 1552-1558 © 2010 Elsevier Science, used with 
permission). 
In humans, 15 ARFGEFs have been discovered and they share a conserved 
catalytic Sec7 domain of approximately 200 amino acids,(5) while 31 discovered human 
ARFGAPs are categorized into 10 subfamilies based on the sequence similarity of GAP 
and other functional domains (Fig 1.3).(20) All ARFGAPs share a catalytic GAP domain 
of approximately 130 amino acids in which a characteristic zinc finger motif 
(CX2CX16CX2CX4R) and an arginine residue are highly conserved.(21)  
1.1.2 ARFGAP family proteins  The ARFGAP activity was initially discovered 
in 1994.(8) It was shown that a crude extract from bovine brain could stimulate GTP 
hydrolysis catalyzed by mammalian ARF1. Both soluble (20-40%) and particulate 
fractions (60-40%) of the brain extract have GTPase activating activity. Enrichment of 
this activity was observed by extraction with 0.75 M NaCl. Heating or trypsin treatment 
will reduce more than 90% of this activity. This activity was then defined as the property 
of ARF-GTPase activating protein (ARFGAP). A few months later, ARFGAP1 was 
cloned and purified as the first member of the ARFGAP family.(22) A zinc finger motif 
near the N-terminus of ARFGAP1 was identified as the key requirement for its catalytic 
activity. The majority of active ARFGAP1 was localized to the Golgi complex, while 
inactive ARFGAP1 diffused to cytosol after the inactivation of ARF.(7,15,23-26) Since 
then, 30 other ARFGAPs have been identified in the mammalian systems. Further study 
suggested that the GAP domain is ancient and conserved in R. norvegicus, C. elegans, D. 
melanogaster, A. thaliana, S. cerevisiae and Gallus gallus.(21)  
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1.1.3 Domain structures of ARFGAP family proteins  ARFGAP1 is the first 
member of the ARFGAP family proteins, with a molecular weight of 45 kD. The GAP 
domain of ARFGAP1 is located at the N-terminus and the remaining region contains two 
ARFGAP1 lipid-packing sensors (ALPS) motifs (Fig 1.3).(20) The ARFGAP2 subfamily 
lacks the ALPS motifs and shares little sequence similarity with ARFGAP1 except the 
GAP domain. ADAP subfamily is composed of a GAP domain and two PH domains. 
SMAP subfamily only shares 47% sequence similarity: SMAP2 has a calm BD domain 
(CB) and a clathrin-box (CALM) while SMAP1 does not have a CB domain. AGFG 
subfamily contains a GAP domain and 10 phenylalanine-glycine repeats (FG). GIT 
subfamily shares a GAP domain, three ankyrin repeats (27), a Spa-homology domain 
(SHD), coiled-coil (CC) and Paxillin binding sites (PBS). The typical ASAP subfamily 
has a Bin/Amphiphysin/Rvs (BAR) domain, a pleckstrin homology (PH) domain (28), a 
GAP domain, three ankyrin repeats (ANK), a cluster of three Proline-rich (PxxP) motif 
(Pro(PxxP)3), eight tandem Proline rich  (D/ELPPKP) motifs,  and a Src homology 3 
domain (SH3). ACAP subfamily contains a Bar domain, a PH domain, a GAP domain 
and ANK. AGAP subfamily consists of a GTP-binding protein-like domain (GLD), a PH 
domain, a GAP domain and ANK. The ARAP subfamily has a sterile α-motif (SAM), 
two PH domains, a GAP domain, ANK, another two PH domains, a RhoGAP domain, a 
Ras association motif (RA) and another PH domain. 
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Figure 1.3 Domain organization of human ARFGAP subfamilies and structure of 
GAP domain of ARFGAP1 (This figure was adapted from (20). Kahn, R. A., Bruford, 
E., Inoue, H., Logsdon, J. M., Nie, Z., Premont, R. T., Randazzo, P. A., Satake, M., 
Theibert, A. B., Zapp, M. L., and Cassel, D. (2008) J Cell Biol 182, 1039-1044) 
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1.2 Roles of ARFGAPs in Cellular Processes  
ARFGAPs are primarily considered as negative regulators of ARFs before 
numerous studies have shown that most ARFGAPs also served as effectors for other 
proteins and lipids due to their multi-domain structures.(1,2,4,29-32) ARFGAPs 
containing catalytic domains other than ARFGAP could also regulate other protein 
family through their enzymatic activity. For instance, ARAPs containing Rho GAP 
domains catalyze the hydrolysis of GTP that bind to the RhoA GTPase. (28) 
ARFGAPs have a variety of interacting partners due to their multi-domain 
structures. The functions of interacting proteins dictate the roles of ARFGAPs for 
membrane traffic, cellular signaling and cytoskeleton reorganization (Fig 1.4).  
  
Figure 1.4 Selected ARFGAPs protein complexes involved in receptor trafficking, 
cell migration and invasion. Several ARFGAPs related to receptor trafficking, focal 
adhesion turnover, cell migration/spreading or tumor invasion are illustrated with their 
interacting proteins and the corresponding ARF substrates . The GAPs that use ARF1 or 
ARF6 as a substrate are colored in blue or yellow, respectively. The GAPs whose 
substrate specificity is controversial or those that may use ARF5 as the substrate are 
 7 
 
colored in green. (This figure was reprinted from from (33). Inoue, H., and Randazzo, P. 
A. (2007) Traffic 8, 1465-1475. © 2007 Blackwell Publishing Ltd, used with permission)  
1.2.1 Membrane traffic  Several ARFGAPs are involved in regulating membrane 
traffic. For example, ERD2 is a transmembrane receptor that mediates retrograde 
transport of ER-resident proteins from the Golgi to the ER. ARFGAP1 binds to p24 cargo 
proteins and to ERD2 to regulate cargo sorting.(34-36) ARFGAP1 was also indicated to 
bind to coatomer and clathrin AP1 to control membrane traffic.(37,38) The binding to the 
coatmer was reported to stimulate the activity of ARFGAP1 by 10-1,000 fold. (21) 
(39)Another ARFGAP, ACAP1, binds to transferrin receptor (TfR), cellubrevin, and 
integrin-β1 to serve as novel coat or adaptor protein in the recycling compartments.(40,41) 
In addition, SMAP proteins interact with clathrin to drive the formation of transport 
intermediates from both the plasma membrane and the trans Golgi network.(42,43) 
Furthermore, AGAP1 and AGAP2 interact with clathrin adaptor proteins, AP3 and AP1, 
respectively, to regulate the endocytic compartments.(34) Finally, ASAP1 interacts with 
CIN85 to accelerate the recycling of EGF and EGFR,(44) and also coordinates with 
POB1 and RalBP to regulate actin cytoskeleton and membrane traffic.(45,46) ASAP2 has 
also been shown to bind to the SH3 domain of amphiphysin IIm to function in synaptic 
vesicle endocytosis.(47) It was suggested that the ARFGAPs function as a subunit of a 
vesicle coat protein similar to the role of Sec23 in ER to Golgi transport mediated by 
COPII vesicle coats.(48) 
1.2.2 Cellular signaling  GIT1, AGAP2 and ARAP3 interact with related 
enzymes to control the levels of important phosphoinositol lipids in cellular signaling. 
GIT1 binds to phospholipase C gamma (PLC-γ), which catalyzes the hydrolysis of PIP2 
to IP3.(46) The interaction between AGAP2 and phosphatidylinositol 3-kinases (PI3K) 
 8 
 
could prevent neuronal apoptosis.(47,49,50) ARAP3 binds to phosphatidylinositol 5-
phosphatase (SHIP2) to negatively regulate PI3K signaling.(51) In addition, GIT1 
interacts with Rac1, Cdc42, p21-activated kinase (PAK), PAK-interacting exchange 
factor (PIX), MEK1, and paxillin.(52) The interaction between GIT1 and PAK are shown 
to regulate cytoskeletal dynamics by inhibiting Rac1 and Cdc42. GRK2 recruits and 
binds to both GIT1 and GIT2 to mediate internalization of the G-protein-coupled receptor 
(GPCR).(52,53) Fyn, a Src family kinase, phosphorylates AGAP2 and prevents 
degradation of AGAP2 during programmed cell death in the anti-apoptotic signaling 
pathway.(54) The interaction between AGAP2 and Akt is essential to this pathway as 
well.(55,56) ASAP1 binds to focal adhesion kinase (FAK) to mediate the localization of 
paxillin and affect cell motility.(57) Src and Pyk2 bind to and phosphorylate ASAP1 to 
inhibit the GAP activity of ASAP1.(58) ARAP1, ARAP2 and ARAP3 containing Rho 
GAP domains interact with RhoA, a Rho GTPase to regulate actin and actin-associated 
structures.(51,59) ARAP3 also regulates peripheral actin ruffles by binding to Rap1 
GTPase.(51) 
1.2.3 Cytoskeleton reorganization GIT1 interacts with paxillin to regulate focal 
adhesion (FA) dynamics and ultimately affect cell adhesion, spreading and migration.(60) 
ASAP1 binds to cortactin to regulate actin cytoskeleton(18,61,62) and the 
ASAP1/cortactin complex uncovers the crosstalk between the highly tubulated 
membranes and polymerized/branched actin.(26,51) GIT2 and ASAP2 also interact with 
paxillin and related proteins to regulate FAs.(45,55) ACAPs bind to bacteria-derived 
intracellular peptidoglycan sensor proteins, NOD1 and NOD2, and vaccinia virus protein 
KILT that are associated with changes in actin or membranes.(55,62,63) 
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1.3 Models of ARFGAP Functions in Cell Signaling 
ARFGAP1 and ARFGAP2/3 are the simplest ARFGAPs in domain structures and 
studies on them form the basis for many models of the ARFGAP functions. Initially, 
ARFGAPs were proposed to only function as negative regulators of ARF signaling. In 
the prevailing model, the cycle of active ARF1 and inactive ARF1 is linked to coat 
association and dissociation from membranes.(2,34,64-67) Although a variety of 
modifications to this model have been proposed, the central hypothesis is that active 
ARF1-GTP is critical for recruiting coat proteins on the membrane while its hydrolysis 
would release the coat proteins from the membranes. In this model, the function of 
ARFGAP1 is to catalyze hydrolysis of ARF1-GTP to induce coat dissociation. The GTP 
hydrolysis is also dependent on the assembling of coat promoters into a vesicle coat. 
1.3.1 Membrane curvature sensing  The cellular functions of ARFGAPs have 
been proposed in several conflicting models.(21,68-70) The hydrolysis of GTP on ARF1 
requires the recruitment of ARFGAP to the membrane, where the active myristoylated 
ARF1 is localized. Previous studies have emerged into two regulatory mechanisms for 
ARFGAP1. In one model, GAP activity is stimulated by coat protein-coatomer and is 
inhibited by cargo proteins.(25,64,71,72) The second and more extensively studied model 
involves membrane curvature sensing of ARFGAP1 (Fig 1.5).(30,73-77) In this model, 
ARFGAP1 is able to sense membrane curvature through the ARFGAP1 lipid-packing 
sensor (ALPS) motifs. The ALPS motif associates with the exposed hydrophobic interior 
of the bilayer to force bending of the membrane.(73) During this process, the two ALPS 
motifs will transform from random coils into amphipathic helix structures.(74) The 
activity of ARFGAP1 increases with the decreasing size of the curved surface. 
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Figure 1.5 GTP hydrolysis and COP dynamics: a complex issue (A) The typical G-
protein activation cycle. The GEF and GAP regulate the functions of the G protein. (B) 
The assembly–disassembly cycle of the protein coats is not necessarily in phase with the 
GTPase cycle. The first coatbuilding unit is a recently formed 1:1 complex between Arf-
GTP and a COP complex wandering at the membrane surface by lateral diffusion. The 
second is an older unit, which has been incorporated in the coat lattice. (This figure was 
reprinted from (67), Antonny, B., Bigay, J., Casella, J. F., Drin, G., Mesmin, B., and 
Gounon, P. (2005) Biochem Soc Trans 33, 619-622. © 2005 Biochemical Society, used 
with permission)  
The model of membrane curvature sensing is attractive and has been extensively 
demonstrated in numerous experiments.(67,75,77-79) However, the model has its own 
limitations. First, although multiple ARFGAPs are involved in membrane traffic, the 
ALPS motifs are only present in ARFGAP1.(74) Therefore, expanding this model to 
other ARFGAPs is conceptually challenging, especially for other large ARFGAPs with 
additional domains. Second, ASAPs with BAR domains are not as sensitive as 
ARFGAP1 to curvature changing, although the primary role of BAR domain is reported 
to sense membrane curvature.(30,74,80,81) Third, cargo sorting is not involved in this 
model.(30) 
1.3.2 Cargo sorting and coatomer  In ARFGAP family proteins, at least one 
member of eight subclasses has confirmed GAP activity. However, ADAPs do not have 
detectable GAP activity in vitro.(72) Therefore, an additional model is proposed where 
ARFGAPs function as ARF effectors as well as terminators (Fig 1.6).(82) In yeast, four 
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ARFGAPs (Gcs1p, Glo3p, Age1p and Age2p) expressed from a high copy plasmid 
suppressed a loss-of-function allele of ARF1(2,83) suggesting that ARFGAPs function as 
downstream effectors of ARFs. Structure evidences suggested that both the yeast 
ARFGAP1 Gcs1p and the ARFGAP2/3 homologue Glo3p interact with SNARE proteins 
to induce the recruitment of ARF1p and coatomer to the SNAREs.(84-86) It is proposed 
that the formation of the primer complexes is required for vesicle transportation. In other 
studies, the most intriguing finding was that COPI vesicles only contain ARFGAP1 
instead of complex of ARFs and ARFGAPs. In vivo data confirmed that COPI persists on 
membrane after the dissociation of ARF.(87) In addition, ARF was not detected in 
proteomic analysis of the COPI coated vesicles(66,88-91) further  indicating that 
ARFGAP1 plays a critical role in this type of cargo sorting. 
Figure 1.6. Scheme of the dual role of ARFGAPs. ARFGAPs have a role as ARF 
effectors in helping recruit cargo and play a vital part in transport vesicle formation. This 
role does not require GAP activity. The second and more established role is to function 
together with ARF as a heterodimeric GTPase, which promotes coat-cargo association 
and coat polymerization.(This figure was reprinted from (31) Spang, A., Shiba, Y., and 
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Randazzo, P. A. (2010) FEBS Lett 584, 2646-2651. © 2010 Federation of European 
Biochemical Societies, used with permission)  
 
 
Figure. 1.7. Model for the role of the PH domain in autoinhibition of ASAP1 GAP 
activity. (1) The PH domain interacts with the GAP domain in the absence of PIP2. (2) 
PIP2 binds to the PH domain, leading to the exposure of the GAP domain. (3) The GAP 
domain interacts with ARF-GTP and catalyzes GTP hydrolysis. (This Figure was 
reprinted from (92), Randazzo, P. A., and Hirsch, D. S. (2004) Cell Signal 16, 401-413. 
© 2003 Elsevier Inc, used with permission)  
The function of ASAP1 has been examined extensively. PIP2 and PA enhance 
GAP activity approximately 10,000 fold.(93,94) It is proposed that PIP2 binds to the PH 
domain and induces a conformational change in the ARFGAP domain.(93) In this model, 
the PH domain binds to the catalytic GAP domain and blocks the interaction of ASAP1 
with ARF-GTP (Fig 1.7).(95) The binding of PIP2 to the PH domain releases the catalytic 
site and consequently stimulates GAP activity. However, more evidences are required to 
support this model. 
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1.4 Disease Relevance of ARFGAPs 
ARFGAPs are involved in various diseases (Fig 1.8). For example, ASAP1 is 
amplified and overexpressed in uveal melanomas and in colorectal, prostate, and breast 
carcinomas.(16,96-99) Overexpression of ASAP1 causes increased cell motility in low-
grade melanoma cells, while siRNAs against ASAP1 reduce cell migration in ASAP1-
overexpessing cells.(16) Furthermore, overexpression of ASAP1 correlates with poor 
metastasis-free survival and prognosis in colorectal cancer patients. (100) 
 
Figure 1.8. Disease relevance of ARFGAP family proteins  
Another ARFGAP, GIT1, was involved in the altered membrane trafficking that 
contributes to Huntington’s disease.(100,101) Aggregation of a huntington mutant 
protein is correlated with increased expression of a catalytic dead GIT1 mutant.(102) In 
neurons of patients with Huntington’s disease, the mutations of GIT1 were observed, and 
these mutants may represent the catalytic dead GIT1.(102) GIT1 and GIT2 also bind to 
the presynaptic neuronal proteins to regulate release of presynaptic vesicles.(103,104) 
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GIT proteins were also involved in HIV infectivity. The inactivation of ARF6 by GITs 
are likely to mediate downregulation of major histocompatibility complex (MHC) class I 
on the host cell after infection by the viral protein Nef.(105)  
ADAP1 is involved in Alzheimer's disease through its interaction with casein 
kinase I and nucleolin.(106-108) ACAP1 mRNA level is increased in the inflamed 
mucosa of patients with inflammatory bowel disease.(109,110) AGAP1 was found to be 
an intriguing candidate gene in autism.(111) Despite the implication of ARFGAPs in 
these diseases, the detailed mechanisms by which ARFGAPs contribute the disease 
development are not well known. Regulators of ARFGAPs would help better understand 
the roles of ARFGAPs in these diseases. 
  
 15 
 
1.5 Regulation of ARFGAP Activity 
The regulation mechanism of ARFGAP is not completely resolved. The catalytic 
mechanism of other GAPs, such as Ras and Rho, has been elucidated.(112,113) Both 
structural and biochemical studies lead to an “arginine finger” model for catalysis of GTP 
hydrolysis.(112-115) In this model, GAPs of Ras and Rho GTPases supply a critical 
arginine residue, which is missing in the GTPases. Mutation of the arginine residue 
caused a reduction of GAP activity. (112-115) 
1.5.1 Crystal structures of ARFGAPs  Currently, three crystal structures of 
ARF-ARFGAP pairs have been resolved.(21,116,117) In the crystal structure of ARF-
GDP and ARFGAP1, the conserved arginine of ARFGAP1 was remote from the catalytic 
center.(21) In biochemical assays, coatomer accelerated the GTP hydrolysis by 1,000-
fold.(21) This finding led the authors to propose that the catalytic arginine was provided 
by coatomer. In contrast, some other biochemical studies have demonstrated a critical 
catalytic role for the conserved arginine of ARFGAP1.(68,116) Structure and 
mutagenesis investigation of GA-PAPβ indicated that the conserved arginine residue 
plays an important role in ARFGAP activity.(68,116) In a recent crystal structure of ARF 
and ASAP3 in the transition state, the conserved arginine of ASAP3 is clarified to be the 
catalytic residue (Fig 1.9).(117) Mutation of the Arg469 to Ala abolished the GAP 
activity.(117) Furthermore, the authors discovered that calcium ions stimulated GAP 
activity of ASAPs, but not other members of ARFGAP family. 
 16 
 
 
Figure 1.9. Overall structure and superimpositions. (A) Ribbon representation of the 
ARF6-GDPAlF3ASAP3 structure, with the ASAP3 GAP domain in cyan, the ankyrin 
domain in blue, and ARF6 in green, and with its switch I in yellow and switch II in 
gray.(B) Comparison of ARF6-GDPAlFxASAP3 with ARF1-GDPARFGAP1 reported 
previously (118), obtained by superimposition of ARF1 with ARF6, with ARFGAP1 in 
dark pink, and ARF6GDP-AlF3-ASAP3 as in Figure 1.9 A, leaving out the ankyrin 
repeats for clarity.(This Figure was reprinted from (117). Ismail, S. A., Vetter, I. R., Sot, 
B., and Wittinghofer, A. (2010) Cell 141, 812-821. © 2010 Elsevier Inc, used with 
permission)  
1.5.2 Biochemical studies  Besides the structural studies on ARFGAPs, extensive 
biochemical experiments have been carried out to understand other lipid-based regulators 
of ARFGAP activity.(8,68,75,77,81,93,94,119,120) PIP2 was shown to stimulate the 
ARFGAP1 activity by 30-fold.(8) In the presence of diacylglycerols (DAG), the rate of 
GTP hydrolysis was also accelerated by 10-fold.(119) Extensive experiments have been 
carried out to support that the activity of ARFGAP1 increases with the decreased size of 
curved membrane.(67,75,77,79) However, the detailed regulation mechanism of 
ARFGAPs is not well understood. 
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1.6 Peptide and Small Molecule Regulators of ARFGAPs 
Currently, there are no effective small molecule inhibitors of ARFGAPs. Because 
cargo proteins bind to coatomer and ARFGAP to form a complex, peptides from the 
cytoplasmic tail of p24 cargo proteins were synthesized and found to inhibit the GAP 
activity of ARFGAP1 and ARFGAP2.(64,121) However, the inhibitory effect was 
nonspecific and coatomer independent. Later, peptides from several p24 family members 
p23 and p25 were also found to enhance GAP activity of ARFGAP1 and ARFGAP2.(68) 
These results are in conflict with the current regulator mechanism in which activation of 
ARFGAP occurs after vesicle assembly. 
Understanding the molecular basis of how ARFGAPs interact with endogenous 
partners are helpful to understand the physiology and pathology of ARFGAPs. Small 
molecule regulators such as enzyme inhibitors and activators could bind to enzymes and 
alter their activities. Such molecules typically have molecular weight less than 800 
Daltons, are cell permeable, and have been powerful tools in biochemistry, molecular 
biology, and pharmacology. Similarly, small molecule regulators of ARFGAPs would be 
useful tools to understand how ARFGAPs contribute to normal and aberrant development. 
In this thesis, I will describe our efforts in developing small molecule regulators of 
ARFGAPs to dissect their cell signaling. 
  
  
 
 
Chapter 2.  
Inhibition of ARFGAP1 Activity by QS11: Mechanism of Action and Analog 
Synthesis  
 
2.1 Introduction 
Small molecule regulators of ARFGAPs will be useful tools to study the functions 
of ARFGAPs in cellular processes, yet only a peptide inhibitor of ARFGAP1 have been 
characterized in biochemical assays. (122) Recently, a small molecule, QS11, has been 
shown to synergize with the Wnt proteins to activate the Wnt/β-catenin signaling 
pathway. (123) In the subsequent target identification process, ARFGAP1 was identified 
as one of the primary targets of QS11. In the presence of QS11, both ARF1-GTP and 
ARF6-GTP showed accumulated levels in NIH 3T3 cells indicating that the GAP 
activities in these cells were inhibited. In addition, in ASAP1-overexpressing MDA-MB-
231 cells, QS11 inhibited cell migration in a dose-dependent manner. Overexpression of 
ARFGAP1 in HEK293 cells abolished synergistic effect of QS11. These results implicate 
that QS11 is an inhibitor of ARFGAPs in vivo. However, whether QS11 inhibits the 
activities of ARFGAPs in in vitro biochemical assays and what is the detailed mechanism 
of this inhibition are not well understood.  
Preliminary structure-activity relationship studies of QS11 were also carried 
out.(123) One key finding was that the biphenyl substitution at the N9 position in QS11 is 
critical for its activity; Substitution of biphenyl group with either phenyl or (p-
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trifluoromethyl)phenyl yields more than 10-fold decrease in activity. Replacement of the 
aryloxy group at the C2 position with amino groups also leads to reduced activity. 
Furthermore, the stereochemistry of the substituent at the C6 position is important as the 
enantiomer of QS11 does not show synergistic activation with the Wnt proteins.  
In this chapter, I will describe our efforts to understand the molecular mechanism 
by which QS11 inhibits the GAP activity of ARFGAP1, and to further modify QS11 to 
generate more active and water-soluble analogs.  
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2.2 Results and Discussion 
2.2.1 Generation of purified ARFGAP1 and ARF1  Human ARFGAP1 has 415 
amino acid residues and contains the GAP domain and two ALPS motifs (Fig 2.1A). The 
WETF sequence in rat ARFGAP1 interacts strongly with clathrin adaptors AP1 and AP2 
whereas the C-terminal peptide (
405
AADEGWDNQNW) binds to coatmer(124). To map 
which region of ARFGAP1 is critical for its interaction with QS11, we generated six 
different ARFGAP1 proteins that include [1-136]ARFGAP1, [1-257]ARFGAP1, [1-
257]ARFGAP1[L207D], [1-257]ARFGAP1[L207D/V279D], full-length ARFGAP1, and 
[1-415]ARFGAP1[R50K] (Fig. 2.2). The expression constructs for the first four proteins 
were kindly provided by Dr. Jonathan Goldberg (Memorial Sloan-Kettering Cancer 
Center) and Dr. Bruno Antonny (Institut de Pharmacologie Moleculaire et Cellulaire. The 
SF9 cell pellets of full-length ARFGAP1 and ARFGAP1[R50K] are from Dr. Richard 
Premont (Duke Univesity). The proteins were expressed and purified according to the 
literature protocols.(21,77,125) 
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Figure 2.1. ARFGAP1 contains one GAP domain and two ALPS motifs. A. Location 
of the GAP domain and ALPS motifs in ARFGAP1. B. Three critical amino acids-R50, 
L207, and V279 are highlighted in sequences of the GAP domain and two ALPS motifs.  
In Fig 2.2, [1-136]ARFGAP1 represents the minimal residues that are required 
for GAP activity (21) [1-257]ARFGAP1 containing a catalytic domain and an ALPS 
motif has sensitivity on liposome radius similar to that of the full-length ARFGAP1.  The 
GAP activity of [1-257]ARFGAP1 increases slightly in the presence of liposome (75) 
while the introduction of mutation L207D decreases its binding affinity with liposome 
and GAP activity. (75,77) The full-length [1-415]ARFGAP1 has been shown to bind with 
QS11. (123) Its mutant [1-415]ARFGAP1[R50K] does not possess GAP activity due to 
the absence of the arginine finger.(29,68,120,126,127) The double mutations 
L207D/V279D decrease binding to liposome and the GAP activity in liposome with 
either small or large curvature. 
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Figure 2.2. Domain structures of various truncations and mutants of ARFGAP1. 
We chose ARF1 as the substrate for ARFGAP1 because the crystal structure of 
ARF1 and GAP domain of ARFGAP1 has been solved and the detailed kinetic studies on 
ARFGAP1-catalyzed hydrolysis of ARF1-GTP have been carried out.(21,68) Under 
physiological conditions, ARF1 is myristoylated and localized at the Golgi membrane 
when it is GTP-bound. A truncated ARF1 with the N-terminal 17 amino acid residues 
deleted has also been widely used in enzymatic assays because it is soluble and 
technically less challenging to prepare in large quantities. Consequently, we have purified 
both mysritoylated ARF1 and [△17]ARF1.(21,122,128) The expression construct for 
myristoylated ARF1 was obtained from Dr. Paul Randazzo (National Cancer Institute) 
while that for soluble ARF1 was obtained from Dr. Jonathan Goldberg (Memorial Sloan-
Kettering Cancer Center). 
2.2.2 QS11 inhibits the activity of  full-length ARFGAP1 but not that of [1-
136]ARFGAP1 Varieties of phosphoinositol lipids stimulate GAP 
activity.(8,75,82,94,119) For instance, phosphatidylinositol 3,4,5-trisphosphate (PIP3) 
enhances the GAP activity of ASAP1 while phosphatidylethanolamine (PE) and 
diacylglycerol (DAG) stimulate the GAP activity of full-length ARFGAP1.(82,119) To 
optimize the activity assay conditions, we first investigated how the lipisome system 
containing various lipids alters the GAP activity of ARFGAP1. Consistent with the 
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literature, we observed that DAG and PE significantly enhanced the hydrolysis of ARF1-
GTP (Fig 2.3). We then tested QS11 in the ARFGAP reaction composed of myristoylated 
ARF1, full-length ARFGAP1 and DAG/PE-stimulated liposome system. When treated 
with 10 μM QS11, the GAP activity of ARFGAP1 was inhibited by approximately 80% 
compared to the control where either DMSO or an inactive analog, QS11-NC, was used 
(Fig 2.4). To further investigate how QS11 inhibits ARFGAP1, we employed the soluble 
[△17]ARF1 and the truncated [1-136]ARFGAP1 for the enzymatic reaction. It has been 
demonstrated that this system can still hydrolyze GTP, but at a much slower rate 
compared to the system containing myristoylated ARF1 and full-length ARFGAP1. More 
importantly, both the truncated ARFGAP1 and ARF1 are soluble, making the enzymatic 
reactions easier to handle. However, when treated with QS11, the GAP activity of [1-
136]ARFGAP1 was not inhibited (Fig 2.5). We then measured the binding affinities 
between QS11 and [1-136]ARFGAP1 by isothermal titration calorimetry (ITC) (Fig 2.6); 
QS11 did not bind to the GAP domain.  
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Figure 2.3. Stimulation of ARFGAP1 activity by DAG or PE. Time course of [1–
415]ARFGAP1-catalyzed hydrolysis of ARF1-GTP with liposome containing 
phosphatidylserine (PS) (5%), phosphatidylinositol (PI) (10%), cholesterol (16%) and 
where indicated DAG (15%) or PE (19%). The remaining lipid is phosphatidylcholine 
(PC). Myristoylated ARF1-GDP (0.4 μM) was mixed with liposome (total lipid 
concentration, 400 μM) and exchanged to ARF1-GTP state by adding GTP (40 μM )and 
chelating free Mg
2+
 with EDTA. The concentration of Mg
2+
 was then adjusted to 3 mM  
and [1-415]ARFGAP1 (40 nM) was added to initiate the GTP hydrolysis on ARF.  
 
Figure 2.4. Inhibition of [1-415]ARFGAP1 by QS11. QS11 (20 μM), QS11NC (20 μM) 
or DMSO were incubated with [1-415]ARFGAP1 for 10 min. In the meantime, 
myristoylated ARF1 (0.8 μM) was exchanged with [γ32P] GTP in the presence of 
liposome (400 μM) containing PC (35%), PS (5%), PI (10%), cholesterol (16%), DAG 
(15%) and PE (19%). The mixture containing compounds (20 μM) and [1-
415]ARFGAP1 (16 nM) were then added to myristoylated ARF-[γ32P] GTP (0.8 μM) as 
a ratio of 1:1. The reactions were stopped at fixed time, and the free GTP and hydrolyzed 
phosphate were removed. The membrane–bound radioactivity was measured using 
scintillation counting. The GAP activity in the presence of DMSO was normalized to 
100%.  
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Figure 2.5. No inhibition of [1-136]ARFGAP1 by QS11. QS11 (20 μM) or DMSO 
were incubated with [1-136]ARFGAP1 for 10 min. [△17]ARF1 (10 μM) was exchanged 
with [γ32P] GTP This mixture containing compounds (20 μM) and [1-136]ARFGAP1 (5 
μM) were then added into [△17]ARF-[γ32P] GTP (10 μM) as a ratio of 1:1. The reactions 
were stopped, sperated and record. GAP activity in the presence of DMSO was 
normalized to 100%  
 
Figure 2.6. Binding affinity of [1-136]ARFGAP1 to QS11 as measured by isothermal 
titration calorimetry (ITC). Raw heat data obtained from injections of 100 μM GAP 
domain into the sample cell containing 10 μM QS11.  
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2.2.3 Characterization of binding affinities between QS11 and different 
forms of ARFGAP1  To understand the mechanism of action, we then studied the 
molecular basis of the interaction between ARFGAP1 and QS11. We have generated six 
truncated or mutated ARFGAP1 proteins and used them for the binding studies (Figs 2.2 
and 2.7). Small molecule affinity pull-down and MS analysis were used to identify 
ARFGAP1 as the potential target of QS11 in the previous study. (123) This pull-down 
approach measures the relative levels of the QS11-bound proteins in cell lysates through 
the small molecule matrix. In analogy, we used this method to distinguish the relative 
binding affinities between QS11/QS11NC and different forms of ARFGAP1 (Fig 2.7). 
Compared with the traditional binding assays such as SPR analysis and ITC, this pull-
down experiment is more efficient since multiple proteins and small molecules can be 
evaluated at the same time. 
The affinity matrices were prepared according to the literature protocol.(123) The 
purified ARFGAP1 was then incubated with the packed affinity matrix at 4 
o
C for 2 h. 
Subsequently, the affinity matrix was extensively washed with binding buffer and eluted 
by boiling with Laemmli sample buffer. Samples were separated by SDS-PAGE and 
detected by coomassie blue staining and western blot against ARFGAP1. Full-length 
ARFGAP1 was efficiently enriched by the QS11, but not the QS11NC matrix (Fig 2.7D). 
This result is consistent with previous report that ARFGAP1 in the lysate of HEK 293 
cells was selectively pulled down by the QS11 but not the QS11NC matrix . Interestingly, 
similar amounts of [1-415]ARFGAP1[R50K] proteins bound to the QS11 matrix, 
suggesting that QS11 does not bind this catalytic arginine residue. The catalytic domain 
of ARFGAP1 did not bind to the QS11 matrix at all, in agreement with the result that 
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R50K mutation does not affect the binding affinity between ARFGAP1 and QS11. These 
results indicated that QS11 does not bind to the active site of ARFGAP1. The double 
mutations [1-415]ARFGAP1[L207D/V279D], however, dramatically reduced the binding 
affinity of ARFGAP1 to the QS11 matrix, indicating that these two residues in the ALPS 
motifs play essential roles in the binding of ARFGAP1 to QS11. Along the same line, [1-
257]ARFGAP1 showed much weaker binding affinity to QS11 when compared to the 
full-length ARFGAP1 suggesting that the second ALPS motif plays a more important 
role in binding to QS11. This was further confirmed by western blot analysis. [1-
257]ARFGAP1[L207D] with a single mutation L207D in the first ALPS motif showed 
further reduced amount of ARFGAP1 that bound to the QS11 matrix which is possibly 
due to the partial disruption of the first ALPS motif. These data suggested that the first 
ALPS motif contribute to binding of ARFGAP1 to QS11 but to a less extent than the 
second ALPS motif. Taken together, the two ALPS motifs, especially the second ALPS 
motif, contribute to the interaction between ARFGAP1 and QS11.  
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Figure 2.7. ARFGAP1 pull-down experiments with small molecule matrices. A and B. 
Chemical structures of QS11 (positive) and QS11NC (negative) based small molecule 
matrices (agarose gel). C-H. Pull-down results of six forms of ARFGAP1 by QS11 and 
QS11NC matrices. C. purified, recombinant ARFGAP1 proteins were visualized by 
coomassie blue staining. 1: [1-136]ARFGAP1, 2: [1-257]ARFGAP1, 3: [1-
257]ARFGAP1[L207D], 4: full-length ARFGAP1, 5: [1-415]ARFGAP1[R50K], 6: [1-
415]ARFGAP1[L207D/V279D]. F. the same amounts of samples were detected by 
antibody against ARFGAP1. D and G. Six ARFGAP1s were incubated with QS11 resin 
at 4°C for 2 h, and then, bound proteins were washed, eluted and determined by 
coomassie blue staining and western blot. E and H. Six ARFGAP1s were treated with 
QS11NC resin in the same way.  
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We further validated this interaction in surface plasmon resonance (SPR) assays. 
Purified full-length ARFGAP1, ARFGAP1[R50K], [1-136]ARFGAP1, [1-
257]ARFGAP1, [1-257]ARFGAP1[L207D] or [1-415]ARFGAP1[L207D/V279D] was 
covalently immobilized to a CM5 chip surface. The control channel was treated in the 
same way but without protein immobilization. Ethanolamine was subsequently injected 
to block the unreacted surface. QS11 was then injected for at increasing concentrations (0, 
156, 312, 625, 1,250, 2,500, 5,000, 8,000 and 10,000 nM) in HBS-EP buffer and the 
dissociation of ARFGAP1-QS11 complex was followed for 10 min. SPR analysis 
afforded Kd values of 1.3 ± 0.3 μM for both full-length ARFGAP1 and ARFGAP1[R50K] 
(Fig 2.8). This is consistent with the result that both full-length ARFGAP1 and 
ARFGAP1[R50K] can effectively bind to the QS11 matrix in the small molecule pull-
down assays. The interaction of QS11 with [1-257]ARFGAP1 generated a weaker 
response in RU and did not reach plateau with QS11 at 10 μM (close to its maximal 
solubility). The single mutant [1-257]ARFGAP1[L207D] showed a further reduced 
response. The catalytic domain of ARFGAP1 showed no binding at all in the SPR assays, 
in consistent with the pull-down results. In addition, the double mutant [1-
415]ARFGAP1[L207D/V279D] showed similar effects as the catalytic domain. We 
therefore concluded that QS11 binds to ARFGAP1 through the ALPS motifs. 
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Figure 2.8. Binding affinities between different ARFGAP1 proteins and QS11 as 
measured by surface plasmon resonance (SPR). The proteins were immobilized on 
surfaces of CM5 chips. Equilibrium responses of the binding of QS11 to ARFGAP1 
proteins were plotted against concentrations of QS11. The data were fitted using a 1:1 
binding model to calculate the binding constant Kd.  
2.2.4 QS11 inhibited GAP activity of ARFGAP1  To quantify the inhibition of 
GAP activity by QS11, we first compared the relative capacity of the six ARFGAP1 
proteins as described in the binding experiments in catalyzing the hydrolysis of ARF1-
GTP. We used [γ32P] GTP hydrolysis assay to detect the loss of [γ32P] GTP that was 
bound to myristoylated ARF1 in liposome, which can indirectly report the GAP activity. 
Myristoylated ARF1 was activated in the presence of GTP and [γ32P] GTP, EDTA and 
liposome. Then, MgCl2 was added to stabilize myristoylated ARF-[γ
32
P] GTP. The GTP 
hydrolysis was initiated by adding ARFGAP1 (Fig 2.9). The full-length ARFGAP1 
showed the best activity while the catalytic inactive ARFGAP1[R50K] remains inactive 
at the maximum concentration (29,68,126,127) The double mutant 
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ARFGAP1[L207D/V279D] dramatically reduced the GAP activity probably due to its 
poor affinity to the liposome, which was also observed in another reported intrinsic 
fluorescence ARF-GTP hydrolysis assay.(77) In addition, [1-257]ARFGAP1 showed a 
slightly reduced GAP activity compared to full-length ARFGAP1(77) while [1-
257]ARFGAP1[L207D] dramatically reduced the GAP activity due to the reduced 
interactions with liposome. Finally, the catalytic domain of ARFGAP1 did not exhibit 
good activity under current reaction conditions, possibly due to its weak interaction with 
liposome.  
 
Figure 2.9. Activities of different forms of ARFGAP1. A. Determination of GAP 
activity of ARFGAP1 on GTP hydrolysis. ARFGAP1 was titrated into a reaction 
containing myristoylated ARF-[γ32P] GTP and measured as described under 
“Experimental Procedures”  
Next, dose-dependent inhibition of the GAP activity of each ARFGAP1 was 
evaluated under conditions that the rate of GTP hydrolysis was within the linear range 
(Fig. 2.10). The IC50 for inhibiting the GAP activity of full-length ARFGAP1 by QS11 
was 4.0 ± 0.5 μM. In contrast, none of the other ARFGAP1 proteins can be inhibited at 
10 μM QS11 in the GTP hydrolysis assays. To investigate whether QS11 competitively 
inhibits ARFGAP1, the concentration of QS11 was fixed at the IC50 value but that of 
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ARF1-GTP varied. QS11 inhibited the GAP activity of full length ARFGAP1 across a 
wide range of concentrations of ARF-GTP (Fig 2.11) indicating that QS11 likely 
inhibited ARFGAP1 non-competitively with ARF1-GTP. 
 
 
Figure 2.10. Inhibition of the GAP activity of different ARFGAP1 proteins by QS11. 
QS11 was pre-incubated with ARFGAP1 for 10 min and the reaction was initiated by 
adding myristoylated ARF1-[γ32P] GTP (400 nm) with liposome (0.2 mM). The 
percentage of remained GAP activity was calculated as the ratio of the GAP activity in 
the presence of QS11 to that of DMSO treatment. 
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Figure 2.11. Non-competitive inhibition of ARFGAP1 by QS11 to ARF-GTP 
binding sites. QS11 was at the IC50 concentration (4.0 μM) while the concentrations of 
substrate ARF1-[γ32P] GTP varied from 100 nM to 6.4 μM.  
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2.2.5 Investigation of secondary structures of ARFGAP1  The ALPS motifs in 
ARFGAP1 are random coils in solution and rearrange to α-helix structures when they 
interact with lipid membranes.(67,77,120) The Circular Dichroism (CD) spectra showed 
that adding liposome to the full length ARFGAP1 led to increased absorbance at 208 and 
222 nm. More detailed analysis indicated that the major contribution of this increase in 
absorbance was from the ALPS motifs, especially the first ALPS motif.(77) Mutations in 
the ALPS motifs dramatically decreased or disrupted the increase of the α-helix 
structures.  
We hypothesize that QS11 interacts with the non-structured ALPS motifs to 
prevent the interactions between ARFGAP1 and the lipid membranes. To test this 
hypothesis, we measured the changes of the secondary structures of ARFGAP1 in the 
presence of both QS11 and liposome (Fig 2.12). As expected, ARFGAP1 showed a slight 
increase of α-helix structures in the presence of liposome. When ARFGAP1 is treated 
with both QS11 and liposome, the increased secondary structures were disrupted due to 
reduced interaction between ARFGAP1 and the liposome. This data supports the notion 
that QS11 interacts with the ALPS motifs and disrupts the interactions between 
ARFGAP1 and membrane. 
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Figure 2.12. Far-UV CD spectra of [1-415]ARFGAP1 (1.4 μM) in solution, with 
PC/PS (70:30) liposome (0.5 mM), or with both PC/PS liposome (0.5 mM) and QS11 
(10 μM). 
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2.2.6 Localization of ARFGAP1 in the presence of QS11  The ALPS motifs are 
required for proper localization of ARFGAP1 in Golgi membrane(77,129,130): 
ARFGAP1 majorly localize in Golgi membrane(76,129,130) while mutations in the 
ALPS motifs cause diffused localization of ARFGAP1.(77,129) Consequently, QS11 
should disrupt the Golgi localization of ARFGAP1 to regulate its catalytic action on 
hydrolysis of ARF1-GTP. Dr. Juyoun Beak in our lab thus transfected NIH3T3 cells with 
YFP-ARFGAP1 and treated the resulting cells with QS11 or QS11NC. Preliminary data 
indeed suggested that the Golgi structures were disrupted upon QS11 treatment (Fig 
2.13). We are optimizing the condition and testing the effects of QS11 in these cells.  
Figure 2.13. Effects of QS11 on localization of ARFGAP1. [1-415]ARFGAP1 fused to 
YFP was transiently expressed in NIH 3T3 cells. The cells were then treated with QS11 
(2 μM) or QS11NC (2 μM) for 24 hours before immunostaining with antibody against 
GM130 and YFP. “BF” is defined as “bright field”  
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2.2.7 Working model on how QS11 inhibits the GAP activity of ARFGAP1  
Based on our data, we propose a working model where QS11 regulates the activity of 
ARFGAP1 through hydrophobic interaction with the ALPS motifs which disrupts the 
Golgi localization of ARFGAP1 in the endogenous systems (Scheme 2.1). QS11 non 
competitively inhibites ARFGAP1 activity through the ALPS motifs. Consistent with this 
model, QS11 is a highly hydrophobic compound partly due to the biphenyl rings. In 
addition, four hydrophobic amino acids in the second ALPS region of ARFGAP1 are 
essential for the interaction of ARFGAP1 with lipid membrane and subsequent formation 
of α-helix structures by non-structured ALPS motifs.  
Scheme 2.1. Mode of inhibition of ARFGAP1 by QS11 QS11 binds to the non-
structured ALPS motifs in ARFGAP1 and prevent the interaction of ARFGAP1 with 
lipid membranes, where active ARFs localize.  
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2.2.8 Synthesis of a small library of QS11 analogs  To improve the potency and 
water solubility of QS11, we carried out further SAR studies. The structure of QS11 is 
shown in Fig 2.14. Previous SAR results demonstrate the critical role of the biphenyl 
substitution at the N9 position. Therefore, our initial plan was to vary the C2 and C6 
substitutions with the intention to systematically modify the N9 substitution in the future. 
The route for synthesizing QS11 analogs is similar to what has been described previously 
(Fig 2.15).(123) Briefly, 2,6-dichloro-9H-purine (1) reacted with biphenyl-4-ylmethanol 
via Mitsunobu reaction to provide 9-[(1,1'-biphenyl)-4-ylmethyl]-2,6-dichloro-9H-purine 
(2). Amines (R
1
-NH2) were then added to 9-[(1,1'-biphenyl)-4-ylmethyl]-2,6-dichloro-
9H-purine (2) in the presence of diisopropylethylamine in t-butanol to yield intermediate 
3. Finally, compound 3 was coupled with various aryloxy groups (R
2
-OH) in the 
presence of tris(dibenzylideneacetone)dipalladium and di-tert-butyl(phenyl)phosphine to 
generate the products (4). Six amines and six phenol derivatives (Fig. 2.16) were chosen 
as the building blocks to probe the electronic and steric effects. 2-(2-
aminoethylamino)ethanol (B1) was selected at the C6 position to also improve water 
solubility of the analogs. Using the described synthetic scheme and building blocks, I 
have synthesized twenty-two QS11 analogs and Dr. Zhiquan Song synthesized another 
nine analogs including B1C0, B1C1, B1C2, B1C5, B5C0, B5C1, B5C2, B5C3 and B5C5. 
The chemical structures of all the analogs are shown in Fig 2.17. 
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Figure 2.14. Chemical structure of QS11  
Figure 2.15. Synthetic schemes for the focused library of 2,6,9-trisubstituted purines  
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Figure 2.16. Building blocks selected for analog synthesis 
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Figure 2.17. Chemical structures of 31 analogs 
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Table 2.1 Inhibition effects, binding affinities, and clogP of analogs Note: For B1C0, 
B1C1, B1C2 and B1C5, log D values would be more useful to determine their 
Partition coefficient.  
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2.2.9 Inhibition studies of QS11 analogs  The synthetic analogs were first 
evaluated in ARF-[γ32P] GTP hydrolysis assays where their capacities to inhibit the 
catalytic activity of the full-length ARFGAP1 were tested. Myristoylated ARF1 was 
loaded with [γ32P] GTP in the presence of EDTA and liposome. Then, MgCl2 was added 
to quench the nucleotide exchange reaction. All analogs were first dissolved in DMSO to 
make a stock solution at 10 mM and then diluted into aqueous solution to make the final 
concentration at 20 μM. In a representative reaction, one QS11 analog was pre-incubated 
with ARFGAP1 (16 nM) at room temperature for 10 min and the resulting mixture was 
added to myristoylated ARF-[γ32P] GTP in liposome to initiate the hydrolysis. As fixeded 
time, the reaction was stopped, free GTP and phosphate were separated and the 
remaining membrane-bound [γ32P]ATP was measured by scintillation counting (Table 
2.1).  
Replacing the biphenyl group in QS11 with a phenyl group (QS11NC) 
dramatically abolished the inhibition. This is consistent with the fact that the removal of 
one of the benzene groups of QS11 abolished the synergist effect of QS11 in the Wnt 
reporter assays.(123) Replacing the 5-methyl-2,3-dihydro-1H-indene moiety (QS11) with 
5-methylbenzo[d][1,3]dioxole (B0C1) did not affect the inhibition effect (IC50 of B0C1 is 
3.8 ± 2.4 μM in Fig 2.18). This suggests that replacement with carbons in the 
cyclopentane is tolerable. However, modification of C2 position with naphthalene ring 
(B0C2 and B0C3) is not favored. Interestingly, the (trifluoromethyl)benzene substitution 
(B0C4) at this position totally disrupted the activity of this molecule while the anisole 
modification (B0C5) still demonstrates certain inhibition. These results suggest that the 
ring A in C2 position is important for activity of this molecule.  
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Figure 2.18 IC50 curve of analog-B0C1  
The water solubility of QS11 is a concern when the compound is used in aqueous 
solution. QS11 begins to precipitate beyond 10 μM in aqueous solution. It was shown 
that when Kd and IC50/EC50 of the compound is around low micromolar or high 
nanomolar range, in a number of biochemical and biophysical assays, the concentrations 
of small molecules need to go beyond 10 μM to get sufficient signal for accurate activity 
measurement.(131-133) It is well known that PEGylation can provide water solubility to 
hydrophobic drugs and proteins.(134-137) In order to improve the water solubility of 
QS11, PEG like structure, 2-(2-aminoethylamino)ethanol (B1) was utilized to modify the 
C6 position of QS11. This set of four analogs (B1C0, B1C1, B1C2, and B1C5) indeed 
showed a better solubility in assay buffer (50 mM Hepes pH 7.2, 120 mM KAc, 3 mM 
MgCl2, 2 mM EDTA, 1 mM DTT). No precipitations were observed when the 
concentrations of the analogs were up to 50 μM, yet these four analogs lost the inhibition 
towards ARFGAP1 as tested in enzymatic assays (Table 2.1). 
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Substitution of the C6 position of QS11 with naphthalen-1-ylmethanamine (B2C0) 
significantly decreased the inhibition of the molecule (Table 2.1). The bulky naphthalene 
moiety is not favored at this position. Interestingly, the analog B2C3, with naphthalene 
groups on both C2 and C6 positions, showed moderate inhibition. It is not clear whether 
the moderate inhibition is due to the increased steric effects or aromatic effects provided 
by the substitutions at the C6 position of QS11. 
The removal of the methoxy group in amine part (B3C0) dramatically decreased 
the inhibition effect (Table 2.1). This hydroxyl group is likely to be important to form a 
hydrogen bond with ARFGAP1 for its activity. This hypothesis was further confirmed by 
replacing the hydroxyl group with a methyl formate group in B5C0. This analog B5C0 
and hydroxyl-free analog B3C0 showed similar decreased activity against ARFGAP1. 
Surprisingly, by replacing the cyclopentane moiety (C0) with 1,3-dioxolane (C1), the 
new analog B5C1 almost rescued the inhibition of this molecule. The two oxygen atoms 
in B5C1 are suspected to form hydrogen bonds with the ARFGAP1 which contribute to 
the inhibition.  
The benzene group in the amine part is necessary for maintaining the inhibition of 
this molecule. After removal of this benzene group, all the analogs (B4C0, B4C1, B4C2, 
B4C3, and B4C5) showed dramatically decreased inhibition of ARFGAP1.  
2.2.10 Binding studies of QS11 analogs  The binding affinities, as measured by 
SPR, between ARFGAP1 and analogs were summarized in Table 2.1. The SPR analysis 
is carried out in a similar manner as described previously. Any analog with a saturation 
signal higher than 10 μM will be considered as non-detectable Kd (n.d).  
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QS11NC lacking one benzene ring in the biphenyl group did not bind to 
ARFGAP1. This is consistent with previous results that QS11NC did not inhibit the GAP 
activity in the in vitro GTP hydrolysis assays, did not increase ARF-GTP levels in NIH 
3T3 cells and did not activate the Wnt signaling pathway.  
Interactions between ARFGAP1 and the analogs are not sensitive to substitutions 
at the C2 positions, although the other modifications (B0C1, B0C2, B0C3, and B0C5) 
indeed decreased the binding affinity, except for (trifluoromethyl)benzene (B0C4). The 
substitution at the C2 position of QS11 with (trifluoromethyl)benzene (B0C4) abolished 
the interaction. This is consistent with the disrupted inhibition of this molecule. (Table 
4.1) Substitutions at the C6 position of QS11 with either 2-(2-aminoethylamino)ethanol 
(B1) or naphthalen-1-ylmethanamine (B2) disrupted bindings interactions between QS11 
analogs and ARFGAP1. These results are consistent with the fact that none of these 
analogs could effectively inhibit ARFGAP1 in activity assays. (Table 2.1) The removal 
of the hydroxyl group (B3C0) or the replacement of the hydroxyl group (B5C0) also 
disrupted the binding interactions between QS11 and ARFGAP1. These data suggest that 
the hydroxyl group is important for the interaction with ARFGAP1. After removing the 
benzene group in the amine part (B4C0), the analog lost its binding to ARFGAP1. 
However, with the substitution of a naphthalene group (B4C2) at the C2 position, the 
new analog rescued the binding affinity. The different binding affinities for B4C2 and 
B4C3 are likely due to different orientations of naphthalene. Consistent with the 
inhibition study, B5C1 showed good interaction with ARFGAP1. 
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2.3 Experimental Section 
2.3.1 Expression and purification of ARFs and ARFGAPs  Rat ARFGAP1 and 
human myristoylated ARF1 are used in this work. Full-length ARFGAP1 and its R50K 
mutant are expressed in SF9 cells by Dr. Richard Premont (Duke Univesity) (125,138). 
The other constructs are expressed in bacterial systems.The expression constructs of [1-
257]ARFGAP1, [1-257]ARFGAP1[L207D] and [1-415]ARFGAP1[L207D/V279D] are 
from Dr. Bruno Antonny (Institut de Pharmacologie Moleculaire et Cellulaire). (77,79) 
The expression constructs of [△17]ARF1 and [1-136]ARFGAP1 are from Dr. Jonathan 
Goldberg (Memorial Sloan-Kettering Cancer Center). (21) The single colonies of 
mysritoylated ARF1 are from Dr. Paul Randazzo (National Cancer Institute). (139,140) 
All the proteins were expressed and purified according to literature 
protocols.(21,77,125,139) 
2.3.2 Small molecule pulldown assay and western blot  The small molecule 
affinity matrix was prepared according to the literature. (123) Purified ARFGAP1 was 
added to the packed affinity matrix (30 μl), and bead buffer [50 mM TrisHCl (pH 7.4), 5 
mM NaF, 250 mM NaCl, 5 mM EDTA, 5 mM EGTA, and 0.1% Nonidet P-40] was 
added up to a final volume of 600 μl. After rotating at 4 °C for 2 h, the mixture was 
centrifuged at 14,000 g for 1 min at 4 °C, and the supernatant was removed. The affinity 
matrix was then washed (six times) with cold bead buffer and eluted by boiling with 
Laemmli sample buffer (60 μL) at 95 °C for 5 min. Samples were loaded and separated 
on a 4–20% Tris-glycine gel (Invitrogen). The proteins were detected by coomassie blue 
staining and western blot against anti- ARFGAP1 antibody (Santa Cruz).   
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2.3.3 Measurement of binding affinities by SPR  BIACore 3000 instrument 
(BIACore, GE) was used in this study. The CM5 sensor chip was activated by running 
through a 1:1 mixture of N-hydroxysuccinimide (0.05 M) and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (0.2 M) at 10 μl/min for 7 min. Purified full-length 
ARFGAP1, ARFGAP1[R50K], [1-136]ARFGAP1, [1-257]ARFGAP1, or [1-
257]ARFGAP1[L207D] [100 μg/ml in 10 mM KAc (pH 5.0)] or [1-
415]ARFGAP1[L207D/V279D] [100 μg/ml in 10 mM KAc (pH 4.0)] was then injected 
for 10 min at 10 μl/min to covalently immobilize it to the CM5 chip surface. The control 
channel was treated in the same way but without protein immobilized. Ethanolamine (1.0 
M, pH 8.5) was injected for 7 min to block the unreacted surface. The CM5 chip surface 
was equilibrated in HBS-EP buffer (0.01 M Hepes, 0.15 M NaCl, 3 mM EDTA, and 
0.005% surfactant P20, pH 7.4). QS11 was then injected for 3 min at increasing 
concentrations (0, 156, 312, 625, 1,250, 2,500, 5,000, 8,000 and 10,000 nM) in HBS-EP 
buffer with a flow rate of 20 μl/min, and dissociation of ARFGAP1-QS11 complexes was 
followed for 10 min. The surface was regenerated with 10 mM glycine (pH 2.5). Data 
from at least two independent titration experiments were averaged. Data in the control 
channel were subtracted from that in the corresponding protein channel. Data resulted 
from DMSO injection were further subtracted from those derived from QS11 injections. 
The data were analyzed by fitting into a one-site specific binding mode to calculate the 
binding affinities using Graphpad Prism 5. 
2.3.4 Liposome  Lipids in chloroform or in powder were purchased from Avanti 
Polar Lipids. A lipid film containing (mole percent
 Note
) PC (35%), PE (19%), PS (5%), 
PI (10%), cholesterol (16%), and 1,2-DAG (15%) was prepared by evaporation under 
 49 
 
argon steam for 1 h and followed by drying under vacuum for 1 h. The film was 
resuspended in buffer [50 mM Hepes (pH 7.5), 120 mM KAc, 3 mM MgCl2, 2 mM 
EDTA and 1 mM DTT] and hydrated at for 0.5 h. (77,79) The mixtures were freezed and 
thawed in ethanol/dry ice and warm water batch five times, and then extrude through 
(pore size) 0.03 µm polycarbonate filters using a hand extruder (Avanti). (Note: mole 
percent is the ratio of the moles of a substance in a mixture to the moles of the mixture). 
2.3.5 Radio active GTP hydrolysis assay  Myristoylated ARF1 (800 nM) is 
activated in buffer [50 mM Hepes (pH 7.5), 120 mM KAc, 1 mM MgCl2, 1 mM DTT, 2.4 
μM GTP, 800 nM [γ32P] GTP (specific activity = 6, 000-3, 000 Ci/mmol), 2 μM EDTA 
and 0.2 mM liposome] for 40 min at room temperature. Then, 2 mM MgCl2 was added to 
stabilize myristoylated ARF-GTP. The so-formed myristoylated ARF-GTP is stable on 
ice for up to two days. The GTP hydrolysis was initiated by adding ARFGAP1, stopped 
by diluting with ice cold buffer [50 mM Hepes (pH 7.5), 120 mM KAc, 3 mM MgCl2, 3 
mM EDTA, 1 mM DTT), and separated by filtration through BA 85 with pore size at 
0.45 µm (Millipore). The radioactivity of the membrane-bound [γ32P] GTP was measured 
by a scintillation counter. For IC50 measurement, ARFGAP1 was pretreated with QS11 or 
DMSO in buffer [50 mM Hepes (pH 7.5), 120 mM KAc, 3 mM MgCl2, 3 mM EDTA, 1 
mM DTT, 50 μg/ml BSA). After incubation at room temperature for 10 min, ARFGAP1 
and QS11 mixture was added to myristoylated ARF-GTP at a 1:1 ratio to initiate the 
hydrolysis. The reactions were incubated at indicated time, stopped and analyzed as 
described above. 
2.3.6 Secondary structure measurements by circular dichroism  CD 
spectroscopy was performed on a Chirascan Spectropolarimeter Plus (Applied 
 50 
 
Photophysics). The proteins were dialyzed against buffer [10 mM Tris pH 7.5, 150 mM 
KCl and 1 mM DTT] at 4 °C overnight. The experiments were performed at room 
temperature in a HELLMA quartz cell with an optical path length of 0.1 cm. Each 
spectrum was recorded from 200 to 260 nm with a bandwidth of 1 nm and a speed of 
1.25 s per point. QS11 (10 μM) was added to a  mixture of ARFGAP1 and liposome and 
the spectrum was recorded after incubation for 10 min. Control spectra of liposome or 
QS11 in buffer were subtracted from the protein spectra.  
2.3.7 Golgi localization of ARFGAP1 in the presence of QS11  The procedures 
were similar as previously described (18). Briefly, GFP-[1-415]ARFGAP1 was 
transfected into NIH3T3 cells. The cells were cultured at 37 
o
C with 5% CO2 for 24 h 
before QS11 (2 μM) or QS11NC (2 μM) were added. After another 24 h, the cells were 
fixed for confocal microscopy.  
2.3.8 Chemical synthesis  DIAD (2.58 ml, 26.25 mmol) was added dropwise to a  
mixture of biphenyl-4-ylmethanol (2.42 g, 26.25 mmol ), 2,6-dichloro-9H-purine (2.36 g, 
25 mmol) and PPh3 (3.36 g, 26.25 mmol) in THF (100 ml). The resulting mixture was 
heated to 75 °C (oil bath temperature) for overnight before it was cooled and diluted with 
CHCl3 (50 ml). The layers were separated and the organic fraction was washed with H2O 
and brine, dried over Na2SO4, and concentrated under vacuum. The residue was purified 
by flash column chromatography over silica gel to give 9-[(1,1'-biphenyl)-4-ylmethyl]-
2,6-dichloro-9H-purine (5.68 g, 16 mmol, 64%).  
The commercially available amine-containing building block (0.62 mmol) was 
then added into 9-[(1,1'-biphenyl)-4-ylmethyl]-2,6-dichloro-9H-purine (200 mg, 0.56 
mmol) in the presence of diisopropylethylamine (193 μl, 1.1 mmol)  in t-butanol (2 ml) at 
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room temperature. After stirring at 80 °C overnight, the reaction mixture was cooled and 
diluted with CHCl3 (10 ml). The layers were separated and the organic fraction was 
washed with H2O and brine, dried over Na2SO4, and concentrated under vacuum. The 
residue was purified by flash column chromatography over silica gel to give compound 3.  
Next, compound 3 (0.05 mmol) was mixted with commercial available phenol 
derivatives (0.18 mmol) in the presence of tris(dibenzylideneacetone)dipalladium (2.3 mg, 
0.002 mmol) and di-tert-butyl(phenyl)phosphine (2 mg, 0.0045 mmol) under reflux 
conditions for 2 h. The reaction mixture was diluted with CHCl3 (100 ml) and the layers 
were separated. The organic layer was washed with H2O and brine, dried over Na2SO4 
and concentrated under vacuum. The residue was purified by flash column 
chromatography over silica gel to generate the final analog 4.  
2.3.9 Calculation of ClogP  Chemdraw software was employed to estimate the 
ClogP value of each analog. 
2.3.10 NMR and mass analysis  Each analog was dissolved in deuterated 
chloroform and the proton NMR signal were determined with a Inova 400 MHz NMR 
spectrometer. The analogs were also analyzed with MALDI-TOF Mass Spectrometry 
with alpa-cyano-4-hydroxycinnamic acid as the matrix.. 
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9-(biphenyl-4-ylmethyl)-2,6-dichloro-9H-purine (2): (5.68 g, 16 mmol, 64%). 
1
H NMR 
(400 MHz, CDCl3) δ 8.09 (s, 1H), 7.62-7.57 (m, 4H), 7.55-7.38 (m, 5H), 5.45 (s, 2H). 
(S)-2-(9-(biphenyl-4-ylmethyl)-2-chloro-9H-purin-6-ylamino)-3-phenylpropan-1-ol 
(B0): (144.75 mg, 0.31 mmol, 55%). 
1
H NMR (400 MHz, CDCl3) δ 7.64-7.54 (m, 5H), 
7.44-7.18 (m, 10H), 7.00-6.97 (m, 1H), 5.38-5.28 (m, 2H), 4.58 (br. s, 1H), 3.90-3.88 (m, 
1H), 3.74-3.71 (m, 1H), 3.06-2.96 (m, 2H). 
2-(2-(9-(biphenyl-4-ylmethyl)-2-chloro-9H-purin-6-ylamino)ethylamino)ethyl 
acetate (B1): (97.44 mg, 0.21 mmol, 36%). 
1
H NMR (400 MHz, CDCl3) δ 7.89-7.84 (m, 
1H), 7.56-7.54 (m, 4H), 7.44-7.28 (m, 5H), 5.35 (s, 2H), 4.25 (s, 2H), 3.79 (s, 2H), 3.68-
3.65 (m, 4H), 2.63 (s, 1H), 2.19-2.06 (m, 4H), 2.01 (m, 3H), 1.26 (m, 2H). 
9-(biphenyl-4-ylmethyl)-2-chloro-N-(naphthalen-1-ylmethyl)-9H-purin-6-amine (B2): 
(261.25 mg, 0.55 mmol, 99%). 
1
H NMR (400 MHz, CDCl3) δ 8.08-8.07 (m, 1H), 7.85-
7.82 (m, 2H), 7.56-7.27 (m, 14H), 6.62 (br. s, 1H), 5.28-5.22 (m, 2H). 
9-(biphenyl-4-ylmethyl)-2-chloro-N-phenethyl-9H-purin-6-amine (B3): (237.06 mg, 
0.54 mmol, 97%). 
1
H NMR (400 MHz, CDCl3) δ 7.59-7.55 (m, 5H), 7.46-7.42 (m, 2H), 
7.38-7.22 (m, 9H), 6.01 (br. s, 1H), 5.35 (s, 2H), 3.91 (br. s, 1H), 3.01-2.97 (m, 2H).  
(S)-2-(9-(biphenyl-4-ylmethyl)-2-chloro-9H-purin-6-ylamino)butan-1-ol (B4): 
(219.78 mg, 0.54 mmol, 96%). 
1
H NMR (400 MHz, CDCl3) δ 7.66-7.54 (m, 4H), 7.45-
7.41 (m, 2H), 7.37-7.33 (m, 3H), 7.07 (br. s, 1H), 5.39-5.23 (m, 2H), 4.33 (br. s, 1H), 
4.00-3.96(m, 1H), 3.75-3.71 (m, 1H), 1.76-1.62 (m, 2H), 1.01-0.97 (m, 3H). 
(S)-methyl 2-(9-(biphenyl-4-ylmethyl)-2-chloro-9H-purin-6-ylamino)-3-
phenylpropanoate (B5): (168.98 mg, 0.34 mmol, 60%). 
1
H NMR (400 MHz, CDCl3) δ 
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7.70 (s, 1H), 7.59-7.55 (m, 4H), 7.46-7.41 (m, 2H), 7.37-7.34 (m, 3H), 7.30-7.15 (m, 7H), 
6.39 (br. s, 1H), 5.34 (s, 2H), 4.12-4.09 (m, 1H), 3.74 (s, 3H), 3.32-3.22 (m, 2H). 
(S)-2-(2-(benzo[d][1,3]dioxol-5-yloxy)-9-(biphenyl-4-ylmethyl)-9H-purin-6-ylamino)-
3-phenylpropan-1-ol (B0C1): (26.28 mg, 0.046 mmol, 92%). 
1
H NMR (400 MHz, 
CDCl3) δ 7.60-7.54 (m, 5H), 7.43 (t, J = 7.4 Hz, 2H), 7.38-7.32 (m, 3H), 7.11-7.22 (m, 
3H), 7.01 (s, 1H), 6.90 (s, 1H), 6.81-6.83 (d, J = 8.0 Hz, 1H), 6.74 (s, 1H), 6.88 (dd, J = 
8.0, 4.0 Hz, 1H), 5.95 (d, J = 20 Hz, 2H), 5.25 (t, J = 18 Hz, 2H), 4.31 (br. s, 1H), 3.78-
3.59 (m, 2H), 2.96 (dd, J = 14.0, 6.0 Hz, 1H). MALDI-MS: m/z 572.2 (M + H)
+
. 
(S)-2-(9-(biphenyl-4-ylmethyl)-2-(naphthalen-2-yloxy)-9H-purin-6-ylamino)-3-
phenylpropan-1-ol (B0C2): (25.98 mg, 0.045 mmol, 90%).
1
H NMR (400 MHz, CDCl3) 
δ 7.87-7.80 (m, 3H), 7.67 (s, 1H), 7.59-7.33 (m, 13H), 7.11 (s, 1H), 7.00 (s, 1H), 6.82 (s, 
2H), 6.68 (s, 2H), 5.32-5.23 (m, 2H), 4.68 (s, 1H), 4.13 (s, 1H), 3.64-3.52 (m, 2H), 2.91-
2.61 (m, 2H). MALDI-MS: m/z 578.3 (M + H)
+
. 
(S)-2-(9-(biphenyl-4-ylmethyl)-2-(naphthalen-1-yloxy)-9H-purin-6-ylamino)-3-
phenylpropan-1-ol (B0C3): (25.98 mg, 0.045 mmol, 90%).
 1
H NMR (400 MHz, CDCl3) 
δ 8.02-7.77 (m, 3H), 7.51-7.36 (m, 15H), 7.15 (s, 3H), 6.83 (s, 2H), 6.47 (s, 1H), 5.22 (s, 
2H), 4.04 (br. s, 1H), 3.41 (m, 1H), 2.75 (s, 2H). MALDI-MS: m/z 578.3 (M + H)
+
. 
(S)-2-(9-(biphenyl-4-ylmethyl)-2-(3-(trifluoromethyl)phenoxy)-9H-purin-6-ylamino)-
3-phenylpropan-1-ol (B0C4): (23.80 mg, 0.040 mmol, 80%).
 1
H NMR (400 MHz, 
CDCl3) δ 7.67 (s, 1H), 7.55-7.51 (m, 7H), 7.46-7.33 (m, 6H), 7.22-7.18 (m, 2H), 7.05 (s, 
2H), 6.50 (s, 1H), 5.25 (d, J = 12.0 Hz, 2H), 4.32 (s, 1H), 3.75 (d, J = 12.0 Hz, 1H), 3.64 
(dd, J = 12.0, 4.0 Hz, 1H), 2.94-2.92 (m, 3H), 2.63 (s, 0.71). MALDI-MS: m/z 596.2 (M 
+ H)
+
. 
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(S)-2-(9-(biphenyl-4-ylmethyl)-2-(3-methoxyphenoxy)-9H-purin-6-ylamino)-3-
phenylpropan-1-ol (B0C5): (25.08 mg, 0.045 mmol, 90%).
 1
H NMR (400 MHz, CDCl3) 
δ 7.62-7.56 (m, 5H), 7.46-7.43 (m, 2H), 7.37-7.26 (m, 4H), 7.22-7.15 (m, 3H), 7.03 (s, 
2H), 5.35-5.20 (m, 2H), 4.30 (br. s, 1H), 3.77-3.71 (m, 4H), 3.63-3.59 (m, 1H), 2.96 (dd,  
J = 12.0, 8.0 Hz, 1H), 2.89-2.84 (m, 1H). MALDI-MS: m/z 558.2 (M + H)
+
. 
2-(2-(9-(biphenyl-4-ylmethyl)-2-(2,3-dihydro-1H-inden-5-yloxy)-9H-purin-6-
ylamino)ethylamino)ethanol (B1C0): (18.20 mg, 0.035 mmol, 70%).
 1
H NMR (400 
MHz, CDCl3) δ 7.56-7.54 (m, 1H), 7.44-7.42 (m, 4H), 7.37-7.35 (m, 2H), 7.35-7.34 (m, 
3H), 7.22-7.20 (m, 1H), 7.09-7.07 (m, 1H), 7.00-6.96 (m, 1H), 5.26-5.22 (m, 2H), 3.82-
3.68 (m, 4H), 3.51-3.40 (m, 4H), 2.92 (s, 4H). MALDI-MS: m/z 521.3 (M + H)
+
. 
2-(2-(2-(benzo[d][1,3]dioxol-5-yloxy)-9-(biphenyl-4-ylmethyl)-9H-purin-6-
ylamino)ethylamino)ethanol (B1C1): (17.29 mg, 0.033 mmol, 65%).
 1
H NMR (400 
MHz, CDCl3) δ 7.68-7.67 (m, 1H), 7.57-7.55 (m, 4H), 7.46-7.42 (m, 2H), 7.37-7.35 (m, 
3H), 6.78-6.73 (m, 2H), 6.66-6.58 (m, 1H), 6.01 (s, 2H), 5.25-5.22 (m, 2H), 3.80-3.67 (m, 
5H), 3.54-3.44 (m, 4H), 2.16 (s, 2H), 2.02 (s, 2H). MALDI-MS: m/z 525.5 (M + H)
+
. 
2-(2-(9-(biphenyl-4-ylmethyl)-2-(naphthalen-2-yloxy)-9H-purin-6-
ylamino)ethylamino)ethanol (B1C2): (18.03 mg, 0.034 mmol, 68%). 
1
H NMR (400 
MHz, CDCl3) δ 7.85-7.80 (m, 3H), 7.70-7.63 (m, 2H), 7.56-7.26 (m, 12H), 5.25 (s, 2H), 
3.99 (s, 1H), 3.77 (s, 1H), 3.64-3.44 (m, 4H), 3.27-3.08 (m, 2H), 2.02-1.98 (m, 4H).  
2-(2-(9-(biphenyl-4-ylmethyl)-2-(3-methoxyphenoxy)-9H-purin-6-
ylamino)ethylamino)ethanol (B1C5): (18.88 mg, 0.037 mmol, 73%). 
1
H NMR (400 
MHz, CDCl3) δ 7.65-7.64 (m, 1H), 7.57-7.55 (m, 4H), 7.46-7.42 (m, 2H), 7.37-7.29 (m, 
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4H), 6.85-6.76 (m, 3H), 5.26-6.23 (m, 2H), 3.79-3.68 (m, 7H), 3.51-3.38 (m, 4H). 
MALDI-MS: m/z 511.2 (M + H)
+
. 
9-(biphenyl-4-ylmethyl)-2-(2,3-dihydro-1H-inden-5-yloxy)-N-(naphthalen-1-
ylmethyl)-9H-purin-6-amine (B2C0): (27.52 mg, 0.048 mmol, 95%). 
1
H NMR (400 
MHz, CDCl3) δ 8.02-8.00 (m, 1H), 7.85-7.77 (m, 2H), 7.56-7.27 (m, 15H), 7.18-7.09 (m, 
2H), 7.03-7.01 (m, 1H), 6.21 (s, 1H), 5.28-5.09 (m, 4H), 2.89-2.85 (m, 4H), 2.09-2.04 (m, 
2H). MALDI-MS: m/z 574.3 (M + H)
+
. 
2-(benzo[d][1,3]dioxol-5-yloxy)-9-(biphenyl-4-ylmethyl)-N-(naphthalen-1-ylmethyl)-
9H-purin-6-amine (B2C1): (27.71 mg, 0.048 mmol, 96%).
 1
H NMR (400 MHz, CDCl3) 
δ 8.02-8.00 (m, 1H), 7.86-7.78 (m, 2H), 7.55-7.27 (m, 16H), 6.80-6.76 (m, 3H), 6.35 (s, 
1H), 5.98-5.95 (m, 2H), 5.27-5.21 (m, 2H), 5.10 (s, 2H). MALDI-MS: m/z 578.2 (M + 
H)
+
. 
9-(biphenyl-4-ylmethyl)-N-(naphthalen-1-ylmethyl)-2-(naphthalen-2-yloxy)-9H-
purin-6-amine (B2C2) (28.59 mg, 0.049 mmol, 98%).: 
1
H NMR (400 MHz, CDCl3) δ 
7.96-7.94 (m, 1H), 7.85-7.69 (m, 6H), 7.55-7.20 (m, 17H), 6.42 (s, 1H), 5.18 (s, 2H), 
5.05 (s, 2H). MALDI-MS: m/z 584.2 (M + H)
+
. 
9-(biphenyl-4-ylmethyl)-N-(naphthalen-1-ylmethyl)-2-(naphthalen-1-yloxy)-9H-
purin-6-amine (B2C3): (28.59 mg, 0.049 mmol, 97%).
 1
H NMR (400 MHz, CDCl3) δ 
8.09-8.07 (m, 1H), 7.91-7.73 (m, 5H), 7.52-7.34 (m, 16H), 7.20-7.15 (m, 4H), 6.22 (s, 
1H), 5.15 (s, 2H), 4.93 (s, 2H). MALDI-MS: m/z 584.2 (M + H)
+
. 
9-(biphenyl-4-ylmethyl)-N-(naphthalen-1-ylmethyl)-2-(3-(trifluoromethyl)phenoxy)-
9H-purin-6-amine (B2C4): (26.45 mg, 0.044 mmol, 87%).
 1
H NMR (400 MHz, CDCl3) 
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δ 8.01-7.98 (m, 1H), 7.88-7.80 (m, 2H), 7.56-7.26 (m, 17H), 6.26 (s, 1H), 5.23 (s, 2H), 
5.08 (s, 2H). MALDI-MS: m/z 602.2 (M + H)
+
. 
9-(biphenyl-4-ylmethyl)-2-(3-methoxyphenoxy)-N-(naphthalen-1-ylmethyl)-9H-
purin-6-amine (B2C5): (26.47 mg, 0.047 mmol, 93%). 
1
H NMR (400 MHz, CDCl3) δ 
8.01-7.99 (m, 1H), 7.86-7.77 (m, 2H), 7.54-7.24 (m, 14H), 6.89-6.74 (m, 3H), 6.35 (s, 
1H), 5.24 (s, 2H), 5.09 (s, 2H), 3.75 (s, 3H). MALDI-MS: m/z 564.2 (M + H)
+
. 
9-(biphenyl-4-ylmethyl)-2-(2,3-dihydro-1H-inden-5-yloxy)-N-phenethyl-9H-purin-6-
amine (B3C0): (25.79 mg, 0.048 mmol, 96%). 
1
H NMR (400 MHz, CDCl3) δ 7.63 (s, 
1H), 7.57-7.55 (m, 4H), 7.46-7.42 (m, 2H), 7.37-7.34 (m, 3H), 7.28-7.18 (m, 3H), 7.11-
7.08 (m, 2H), 7.02-7.00 (m, 2H), 6.07 (br. s, 1H), 5.26 (s, 2H), 3.69 (br. s, 2H), 2.95-2.87 
(m, 6H), 2.13-2.04 (m, 2H). MALDI-MS: m/z 538.3 (M + H)
+
. 
2-(benzo[d][1,3]dioxol-5-yloxy)-9-(biphenyl-4-ylmethyl)-N-phenethyl-9H-purin-6-
amine (B3C1): (25.44 mg, 0.047 mmol, 93%). 
1
H NMR (400 MHz, CDCl3) δ 7.63 (s, 
1H), 7.57-7.55 (m, 3H), 7.46-7.42 (m, 2H), 7.37-7.30 (m, 3H), 7.28-7.13 (m, 3H), 6.83-
6.81 (m, 2H), 6.79-6.72 (m, 1H), 5.26 (m, 2H), 3.72 (br. s, 2H), 2.89 (s, 2H). MALDI-
MS: m/z 542.2 (M + H)
+
. 
9-(biphenyl-4-ylmethyl)-2-(naphthalen-2-yloxy)-N-phenethyl-9H-purin-6-amine 
(B3C2): (26.27 mg, 0.048 mmol, 96%). 
1
H NMR (400 MHz, CDCl3) δ 7.90-7.81 (m, 3H), 
7.70 (s, 1H), 7.64 (s, 1H), 7.55-7.32 (m, 12H), 7.12 (m, 3H), 6.91 (br. s, 2H), 5.25 (s, 2H), 
3.64 (s, 2H), 2.82 (s, 2H). MALDI-MS: m/z 548.2 (M + H)
+
. 
9-(biphenyl-4-ylmethyl)-2-(naphthalen-1-yloxy)-N-phenethyl-9H-purin-6-amine 
(B3C3): (26.27 mg, 0.048 mmol, 96%). 
1
H NMR (400 MHz, CDCl3) δ 8.05-8.03 (m, 1H), 
7.92-7.90 (m, 1H), 7.78-7.76 (m, 1H), 7.44-7.34 (m, 12H), 7.26-7.15 (m, 6H), 6.91 (s, 
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2H), 5.94 (br. s, 1H), 5.17 (s, 2H), 3.54 (s, 2H), 2.67 (s, 2H). MALDI-MS: m/z 548.2 (M 
+ H)
+
. 
9-(biphenyl-4-ylmethyl)-N-phenethyl-2-(3-(trifluoromethyl)phenoxy)-9H-purin-6-
amine (B3C4): (25.43 mg, 0.045 mmol, 90%). 
1
H NMR (400 MHz, CDCl3) δ 7.62-7.42 
(m, 11H), 7.37-7.32 (m, 3H), 7.24-7.18 (m, 2H), 7.09 (br. s, 2H), 5.25 (s, 2H), 3.70 (s, 
2H), 2.86 (s, 2H). MALDI-MS: m/z 566.2 (M + H)
+
. 
9-(biphenyl-4-ylmethyl)-2-(3-methoxyphenoxy)-N-phenethyl-9H-purin-6-amine 
(B3C5): (24.25 mg, 0.046 mmol, 92%). 
1
H NMR (400 MHz, CDCl3) δ 7.61-7.54 (m, 5H), 
7.45-7.42 (m, 2H), 7.35-7.32 (m, 3H), 7.28-7.25 (m, 4H), 7.21-7.18 (m, 1H), 7.11 (br. s, 
2H), 6.87-6.77 (m, 3H), 5.95 (br. s, 1H), 5.25 (s, 2H), 3.80 (s, 3H), 3.72-3.70 (m, 2H), 
2.87 (s, 2H). MALDI-MS: m/z 528.2 (M + H)
+
. 
(S)-2-(9-(biphenyl-4-ylmethyl)-2-(2,3-dihydro-1H-inden-5-yloxy)-9H-purin-6-
ylamino)butan-1-ol (B4C0): (22.74 mg, 0.045 mmol, 90%). 
1
H NMR (400 MHz, CDCl3) 
δ 7.58-7.53 (m, 4H), 7.43-7.31 (m, 5H), 7.21-7.19 (m, 1H), 7.05 (s, 1H), 6.97-6.95 (m, 
1H), 6.21 (br. s, 1H), 5.21 (s, 2H), 4.03 (br. s, 1H), 3.76-3.64 (m, 3H), 2.91 (s, 4H), 2.11-
2.09 (m, 2H), 1.62-1.58 (m, 2H), 0.94-0.88 (m, 3H). MALDI-MS: m/z 506.3 (M + H)
+
. 
(S)-2-(2-(benzo[d][1,3]dioxol-5-yloxy)-9-(biphenyl-4-ylmethyl)-9H-purin-6-
ylamino)butan-1-ol (B4C1): (22.91 mg, 0.045 mmol, 91%). 
1
H NMR (400 MHz, CDCl3) 
δ 7.60-7.54 (m, 5H), 7.45-7.41 (m, 2H), 7.36-7.32 (m, 3H), 6.81-6.79 (m, 1H), 6.74 (m, 
1H), 6.67-6.65 (m, 1H), 6.34 (br. s, 1H), 5.99 (s, 2H), 5.21 (s, 2H), 4.06 (br. s, 1H), 3.77-
3.63 (m, 2H), 1.61 (m, 2H), 0.87-0.83 (m, 3H). MALDI-MS: m/z 510.2 (M + H)
+
. 
(S)-2-(9-(biphenyl-4-ylmethyl)-2-(naphthalen-2-yloxy)-9H-purin-6-ylamino)butan-1-
ol (B4C2): (24.22 mg, 0.047 mmol, 93%). 
1
H NMR (400 MHz, CDCl3) δ 7.87-7.85 (m, 
 58 
 
2H), 7.80-7.78 (m, 1H), 7.63-7.61 (m, 2H), 7.53-7.34 (m, 10H), 7.30-7.28 (m, 2H), 6.20 
(br. s, 1H), 5.19 (s, 2H), 3.76 (br. s 1H), 3.62-3.58 (m, 2H), 1.69 (m, 2H), 0.91 (m, 3H). 
MALDI-MS: m/z 516.2 (M + H)
+
. 
(S)-2-(9-(biphenyl-4-ylmethyl)-2-(naphthalen-1-yloxy)-9H-purin-6-ylamino)butan-1-
ol (B4C3): (24.73 mg, 0.048 mmol, 95%). 
1
H NMR (400 MHz, CDCl3) δ 7.36 (s, 1H), 
7.56-7.54 (m, 4H), 7.45-7.42 (m, 2H), 7.35-7.26 (m, 4H), 6.83-6.77 (m, 3H), 6.24 (br. s, 
1H), 5.23 (s, 2H), 4.04 (br. s, 1H), 3.78 (s, 5H), 3.66-3.61 (m, 2H), 2.63 (s, 1H), 1.63 (m, 
2H), 0.93 (m, 3H). MALDI-MS: m/z 516.2 (M + H)
+
. 
(S)-2-(9-(biphenyl-4-ylmethyl)-2-(3-methoxyphenoxy)-9H-purin-6-ylamino)butan-1-
ol (B4C5): (22.28 mg, 0.045 mmol, 90%). 
1
H NMR (400 MHz, CDCl3) δ 7.99-7.97 (m, 
1H), 7.90-7.80 (m, 1H), 7.75-7.73 (m, 1H), 7.63-7.26 (m, 13H), 7.25-7.17 (m, 2H), 6.25 
(br. s, 1H), 5.09 (s, 2H), 3.78-3.48 (m, 3H), 2.63 (s, 1H), 1.77 (m, 2H), 0.93 (m, 3H). 
MALDI-MS: m/z 496.2 (M + H)
+
. 
(S)-methyl 2-(9-(biphenyl-4-ylmethyl)-2-(2,3-dihydro-1H-inden-5-yloxy)-9H-purin-
6-ylamino)-3-phenylpropanoate (B5C0): (23.80 mg, 0.040 mmol, 80%). 
1
H NMR (400 
MHz, CDCl3) δ 7.65 (s, 1H), 7.57-7.55 (m, 4H), 7.46-7.45 (m, 2H), 7.44-7.43 (m, 3H), 
7.24-7.22 (m, 4H), 7.08-7.05 (m, 3H), 6.99-6.97 (m, 1H), 6.26 (br. s, 1H), 5.27 (s, 2H), 
5.09 (br. s, 1H), 3.64 (s, 3H), 3.15 (s, 2H), 2.94 (s, 4H), 2.15-2.09 (m, 2H). MALDI-MS: 
m/z 596.3 (M + H)
+
. 
(S)-methyl 2-(2-(benzo[d][1,3]dioxol-5-yloxy)-9-(biphenyl-4-ylmethyl)-9H-purin-6-
ylamino)-3-phenylpropanoate (B5C1): (21.02 mg, 0.035 mmol, 78%). 
1
H NMR (400 
MHz, CDCl3) δ 7.65 (s, 1H), 7.57-7.55 (m, 4H), 7.46-7.45 (m, 2H), 7.44-7.43 (m, 3H), 
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7.24-7.22 (m, 5H), 7.08 (s, 2H), 6.75-6.66 (m, 3H), 6.22 (br. s, 1H), 5.99 (m, 2H), 5.26 (s, 
2H), 5.03 (br. s, 1H), 3.66 (s, 3H), 3.16 (s, 2H). MALDI-MS: m/z 600.2 (M + H)
+
. 
(S)-methyl 2-(9-(biphenyl-4-ylmethyl)-2-(naphthalen-2-yloxy)-9H-purin-6-ylamino)-
3-phenylpropanoate (B5C2): (24.20 mg, 0.040 mmol, 80%).
 1
H NMR (400 MHz, 
CDCl3) δ 7.88-7.86 (m, 2H), 7.82-7.81 (m, 1H), 7.61-7.29 (m, 14H), 6.96-6.84 (m, 3H), 
6.84 (s, 2H), 6.82 (m, 1H), 6.33 (br. s, 1H), 5.25 (s, 2H), 4.96 (s, 1H), 3.98 (s, 1H), 3.54 
(s, 3H), 3.09 (s, 2H). MALDI-MS: m/z 606.2 (M + H)
+
. 
(S)-methyl 2-(9-(biphenyl-4-ylmethyl)-2-(naphthalen-1-yloxy)-9H-purin-6-ylamino)-
3-phenylpropanoate (B5C3): (25.11 mg, 0.041 mmol, 83%).
 1
H NMR (400 MHz, 
CDCl3) δ 8.01-7.99 (m, 1H), 7.92-7.90 (m, 1H), 7.78-7.76 (m, 1H), 7.52-7.31 (m, 13H), 
7.18-7.10 (m, 3H), 6.91 (s, 2H), 6.19 (br. s, 1H), 5.19 (s, 2H), 4.78 (s, 1H), 3.52 (s, 3H), 
2.93 (s, 2H). MALDI-MS: m/z 606.2 (M + H)
+
. 
(S)-methyl 2-(9-(biphenyl-4-ylmethyl)-2-(3-methoxyphenoxy)-9H-purin-6-ylamino)-
3-phenylpropanoate (B5C5): (23.99 mg, 0.041 mmol, 82%).
 1
H NMR (400 MHz, 
CDCl3) δ 7.55 (s, 1H), 7.46-7.44 (m, 4H), 7.37-7.34 (m, 2H), 7.32-7.28 (m, 8H), 7.07 (s, 
2H), 6.83-6.79 (m, 3H), 6.24 (br. s, 1H), 5.26 (s, 2H), 5.03 (br. s, 1H), 3.79 (s, 3H), 3.65 
(s, 3H), 3.15 (s, 2H). MALDI-MS: m/z 586.2 (M + H)
+
. 
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2.4 Conclusion 
Small GTPases ARFs and their effectors ARFGAPs and ARFGEFs have emerged 
to be therapeutic targets for many cancers and neurological diseases. (5,138,141,142) 
However, there are limited small molecule regulators of these families of proteins. In this 
study, we report the characterization of one small molecule ARFGAP inhibitor, QS11, 
and the molecular basis of its inhibition. QS11 non-competitively inhibits ARFGAP1 
activity in ARF-GTP hydrolysis assay (IC50 = 4.0 ± 0.5 μM). To our knowledge, this is 
the first small molecule ARFGAP inhibitor and demonstrates the feasibility of 
developing small molecules to target ARFGAPs. Interestingly, QS11 inhibits the GAP 
activity through regulating the unique ALPS motifs, particularly the second ALPS motif 
in ARFGAP1, instead of the GAP domain. This interesting mechanism provide novel 
insights into developing more potent and selective ARFGAP inhibitors. Toward that goal, 
we have synthesized and characterized 31 QS11 analogs. Several analogs showed 
promising binding affinities and potencies. 
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2.5 Future Plan 
ARFGAP1 contains two ALPS motifs. It will be interesting to know how much 
each ALPS motif contributes to QS11’s binding to ARFGAP1. Consequently, it would be 
helpful to measure the direct interactions between each ALPS motif and QS11. The 
information on the interaction between [1-415]ARFGAP1[V279D] and QS11 will also be 
useful. Since [1-415]ARFGAP1[V279D] maintains the GAP activity of ARFGAP1(77), 
QS11 could be tested to inhibit its GAP activity. To our knowledge, ALPS motifs are 
present only in ARFGAP1 among ARFGAPs.(76) However, the Bar domain in ASAP1 
plays similar roles as the ALPS motifs in ARFGAP1.(72,81) Is QS11 a specific inhibitor 
for ARFGAP1, or does it also inhibit other ARFGAPs? It would be very likely to 
investigate whether QS11 could interact with the Bar domain in ASAP1 and inhibit its 
GAP activity. ARFGAP1 is also regulated by COPI systems (29,36,126) and interacts 
with several SNARE proteins and coatomer in a GAP-independent 
manner.(21,29,36,64,68,85,87,122) Since QS11 does not interact with the catalytic GAP 
domain, we will test whether these interactions are affected by QS11. In addition, 
coatomer enhances GAP activity of ARFGAP1(21,68,122,127) while a peptide derived 
from p24 is shown to inhibit GAP activity in a coatomer-dependent manner.(122) It 
would also be helpfulto test whether QS11 affects coatomer-dependent GAP activity. 
None of 31 QS11 analogs showed improved activity against ARFGAP1. One 
possibility is that the regions we modified are not the most crucial ones for QS11-
ARFGAP1 interactions. Given the critical roles of the biphenyl substitution at the N9 
position for activity, we will systematically modify this position to generate more potent 
ARFGAP inhibitors.  Considering that the hydrophobic residues (tryptophan, tyrosine 
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and phenylalanine) in the ALPS motifs are responsible for their interaction with lipid 
membranes, we might be able to increase the binding affinity through both hydrophobic 
interactions and hydrogen bonds by modifying the substitution at the N9 position. 
  
  
 
 
Chapter 3. 
High Throughput Fluorescence Polarization Assay for the Enzymatic Activity of 
ARFGAP
1
 
 
3.1 Introduction 
High throughput screening (HTS) has emerged as an integral part of the 
pharmaceutical industry and academic laboratories for basic discovery and drug 
development.(143-145) Using robotics, liquid handling devices, sensitive detectors and 
informatics software, HTS provides an efficient method to investigate large numbers of 
synthetic compounds or genes in miniaturized assays to identify those capable of 
modulating a biological target of interest or a particular biomolecular pathway.(146-148) 
Originally, HTS was primarily utilized by pharmaceutical industry to generate hit 
compounds for further development. Recently, there are growing numbers of academic 
researchers who use HTS to identify chemical probes (tool compounds) for basic 
research.(149-151)  
ARFGAP family proteins have 31 members in human.(20) Despite their crucial 
roles in cell physiologies and human pathologies, no effective small molecule regulators 
have been reported. The zinc figure motif that is responsible for the catalytic activity of 
ARFGAPs is highly conserved among ARFGAPs(20,117,118) while each subfamily of 
ARFGAPs also has distinct functional structures.(20) This provides us a tremendous 
                                               
1 Part of this chapter is taken directly from J Biomol Screen. 2011 Aug; 16(7):717-23. 
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opportunity to develop both pan inhibitors targeting the GAP domain and selective 
inhibitors targeting distinct functional structures of ARFGAPs through HTS. However, 
there is no assay of ARFGAP activity that is amenable for high-throughput screening.  
Conventional ARFGAP activity assays have relied on utilization of radiolabeled 
GTP analogs [32P] GTP and [32P] GTP that behave similarly to the native GTP and can 
be easily detected(152,153). These methods require separation of GTP from GDP either 
through thin layer chromatography or a filter-binding approach, which makes them time-
consuming and only suitable for terminal measurements. Recently, fluorescent guanine 
nucleotide derivatives N-methyl-3’-O-anthranoyl (MANT) and BODIPY have been 
developed(154,155), allowing for G protein assays with greater sensitivity than previous 
fluorescence assays that relied on detection of changes in intrinsic tryptophan 
fluorescence. A number of studies have been reported on use of these fluorescent GTP 
derivatives with low molecular Ras-like G proteins with good sensitivities.(156-159) 
However, these reagents have not been applied to ARF activity assays. Clearly, a high 
throughput ARFGAP assay that can be used for development of small molecule 
regulators is urgently needed. 
In our efforts to dissect ARFGAP-regulated cell signaling, a novel fluorescence 
polarization-based ARFGAP assay has been developed. The Z’ factor of the assay is 0.75 
in 384-well format. When applied to a pilot screen of the Prestwick library of around 
1,000 compounds, the assay demonstrated high reproducibility, reasonable hit rates, and 
suitability for automation. This represents the first assay of ARFGAP enzymatic activity 
that is not based on radiolabeled GTP analogs and can be used for large scale screening to 
generate ARFGAP-selective small molecule inhibitors. 
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3.2 Results and Discussion 
3.2.1 Development of a high throughput fluorescence polarization assay for 
the enzymatic activity of ARFGAP  Fluorescence polarization assay(160) has been 
successfully used to identify small molecule inhibitors of protein-protein interactions. 
Polarization is a measure of the change in the molecular movement of a labeled species 
and is defined as the ratio of the difference between the vertical and horizontal 
components of the emitted light over their sum. Because polarization is a dimensionless 
value, it is independent of the emitted light or the concentration of the fluorophore. These 
features make the FP assay suitable for screening compound libraries in a high 
throughput format to identify small molecule inhibitors. 
Recently, the BellBrook Labs have developed a homogenous, fluorescence 
polarization-based Transcreener Assay for GDP (www.bellbrooklabs.com). Using the 
same strategy, we have validated a novel fluorescence polarization-based ARFGAP assay 
with the GAP domain (residues 6-136) of rat ARFGAP1 and human ARF1 lacking its  
first 17 residues (Fig 3.1). The expression constructs were kindly provided by Dr. 
Jonathan Goldberg (Memorial Sloan-Kettering Cancer Center) and both proteins were 
expressed and purified using published protocols as described in Chapter two. The 
purified GAP domain efficiently catalyzed the conversion of ARF1-GTP to ARF1-GDP 
based on the differential mobility of the two nucleotide-bound forms during native gel 
electrophoresis (Fig. 3.2), demonstrating that both ARFGAP1 and ARF1 are functional. 
In the fluorescence polarization assay, the GAP activity is measured using a 
commercially available assay kit (Transcreener assay) based on fluorescence polarization 
detection of GDP that is generated by the GTP hydrolysis of ARF1. When the fluorescent 
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tracer binds to the antibody, the fluorescence polarization in mP (milli-polarization) is 
high. When the tracer is in free form in the solution, the fluorescence polarization is low. 
As shown in Fig. 3.3, the GTP hydrolysis of ARF1 that is catalyzed by ARFGAP1 can be 
effectively monitored through this method. The fluorescence polarization in mP changed 
from 250 at the start of the reaction to around 80 when in 4 h (Fig. 3.3). Such a big  
change in mP value will make the assay suitable for screening of small molecule 
collections.  
Figure 3.1. Schematic illustration of the assay. The guanosine diphosphate (GDP) that 
is derived from the guanosine triphosphate (GTP) hydrolysis displaces the fluorescent 
tracer that binds to antibody against GDP, leading to mP (milli-polarization) decrease.  
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Figure 3.2. GTPase-activating protein (GAP) domain of ARFGAP1 effectively 
catalyzes the conversion of ARF1-GTP to ARF1-GDP. GAP domain (3.2 μM) was 
added to ARF1-GTP (16.5 μM) for the indicated times prior to native gel electrophoresis 
of the samples. 
 
Figure 3.3. Time course reaction of ARF-GTP hydrolysis in FP assay. GAP domain 
of rat ARFGAP1 (0.5, 1, or 2 μM) was added to ARF1-GTP (2 μM) for the indicated 
times, and the GDP generated from the GAP reaction was detected through fluorescence 
polarization according to the manufacturer’s instructions. For comparison, the reactions 
without adding ARFGAP1 were also carried out.  
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To ensure that the assay conditions are applicable for inhibitor development, the 
kinetics of the ARFGAP1-catalyzed hydrolysis of ARF1-GTP was measured. The 
amount of hydrolyzed GTP was measured for different concentrations of ARF1-GTP 
(Fig. 3.4) by using radiolabeled [γ32P]GTP. The plot of the initial velocity versus ARF1 
concentration was fitted to the Michaelis-Menton equation, and the Km was estimated as 
73.4 μM, consistent with the literature value when truncated ARF1 was used. These data 
collectively suggest that this FP-based assay is suitable for identifying small-molecule 
inhibitors of ARFGAPs.  
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Figure 3.4. The ARFGAP1-catalyzed GTP hydrolysis with different concentrations 
of ARF1-GTP The plot of the hydrolysis rate versus the ARF1 concentration 
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To correlate the mP changes with percentage of GTP hydrolysis, we generated a 
standard curve using defined GTP/GDP ratio (Fig. 3.5). Under the same conditions, the 
GTP hydrolysis can be effectively detected up to 15% conversion, suggesting that the 
assay is ideal for performing ARFGAP assays under initial rate conditions. The amount 
of enzymes used in the assay significantly changed the rate of hydrolysis, with higher 
concentration of ARFGAP1 and ARF1 leading to more rapid mP change (data not 
shown). This feature makes it feasible to complete the assay in a time window that is 
sufficient for sample and plate handling by the screening facility while still achieve 
maximal signal-to-background signal. Finally, the ARF1-GTP was purified through a 
desalting column and was used in the assay; similar kinetics profile was observed (data 
not shown) indicating that the free GTP does not have significant impacts on the assay.  
Figure. 3.5. Standard curve for guanosine triphosphate (GTP) hydrolysis. The 
guanosine diphosphate (GDP) detection reagent was added to GTP/GDP standards 
prepared by mixing different amounts of GDP and GTP. The % GTP conversion = [μM 
GDP/ (μM GDP + μM GTP)] * 100. The total concentration of GDP and GTP is 2 μM.  
3.2.2 Scope of the fluorescence polarization assay  At least 31 ARFGAPs are 
encoded in the human genome, among which approximately 17 have GAP enzymatic 
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activity(161). To test whether the newly developed fluorescence polarization assay can 
also be applied to measure the GAP activities of other ARFGAPs, two distinct ARFGAPs 
(ASAP1 and SMAP2) have also been purified (Fig. 3.6) using literature protocols. As 
shown in Fig. 3B, the GAP activity of both ASAP1 and SMAP2 to catalyze the 
hydrolysis of ARF1-GTP can be effectively monitored (Fig. 3.7). The kinetics profiles 
for ASAP1 and SMAP2 under the same concentrations are different, suggesting that their 
catalytic capacity is different. Taken together, these results suggest that the newly 
developed fluorescence polarization assay can be used to measure the GAP activity of 
different ARFGAPs.  
Figure 3.6. Highly purified human His6-[325-724]ASAP1 and human GST-[1-
163]SMAP2-His6 as assessed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) analysis  
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Figure 3.7. Fluorescence polarization assay monitoring the GTPase-activating 
protein (GAP) activity of SMAP2 and ASAP1. Either ASAP1 (0.2 μM) or SMAP2 (1 
μM) was added to ARF1-GTP (2 μM) for the indicated times, and the guanosine 
diphosphate (GDP) generated from the GAP reaction was detected through fluorescence 
polarization  
3.2.3 Assay development towards high throughput screening  In the design 
and validation of high throughput screening (HTS) assays, an assessment of the screening 
data variability, by measures such as standard deviation (SD) and Z’ factor, is critical in 
determining whether an assay can identify hits with confidence(162). To measure the Z’ 
factor value in our assay, 24 parallel experiments in which the ARF1-GTP was incubated 
with either the GAP domain of rat ARFGAP1 (positive control) or the reaction assay 
buffer (negative control) at room temperature for 2 h was carried out and the 
flurorescence polarization was recorded (Fig. 3.8). The calculated Z’ factor is 0.75,   
indicating that the quality of the assay is good. We also tested the effect of DMSO on the 
change of fluorescence polarization in the reaction (Fig. 3.9).  The assay is robust and 
tolerates up to 10% DMSO in 384-well plates.  
  
 73 
 
Figure 3.8. Assay development toward high-throughput screen. Measuring the Z′ 
factor of the assay. Either GTPase-activating protein (GAP) domain of rat ARFGAP1 (1 
μM, circle dots) or the assay buffer (square dots) was added to ARF1-GTP (2 μM) for 2 h, 
and the guanosine diphosphate (GDP) generated from the GAP reaction was detected 
through fluorescence polarization. Each condition was repeated 23 times. 
 
Figure 3.9. DMSO effect on the assay. The GAP assay as described in Figure 1D was 
carried out in the presence of DMSO at the indicated concentrations. Error bars are SD. 
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3.2.4 Screen of the Prestwick and LOPAC1280 Collection  To further 
demonstrate the utility of this assay, we screened the Prestwick collection of 960 
compounds for ARFGAP regulators in 384-well format at the NIMH Psycoactive Drug 
Screening Center directed by Dr. Bryan Roth. The screen was carried out in triplicates 
and the mean GTP hydrolysis was controlled at around 10% under the screen conditions 
so that both activators and inhibitors can be identified. The mean of the triplicates of each 
well is plotted (Fig. 3.10 A). The coefficient of variation (CV) was 4% and the hit (more 
than 3 SD from the mean of the plate) rate was about 0.4%. One compound, BM11 (Fig. 
3.10 B), showed the most potent inhibition of the ARFGAP activity and the IC50 was 
measured as 1.2 M.  
Figure 3.10. Pilot screen of the Prestwick library. A. The fluorescence polarization 
assay was used to screen the Prestwick collection in 384-well format for small molecule 
ARFGAP regulators. One compound, BM11, showed more than 50% inhibition of the 
GAP activity. B. Chemical structure of BM11; The IC50 of BM11 was measured as 1.2 
M through dose-dependent response experiment. 
In addition, we screened the LOPAC1280 collection of 1280 pharmacologically 
active compounds in the Center for Integrative Chemical Biology and Drug Discovery. 
The screen was carried out in duplicates, and the mean of the duplicates of each well is 
plotted (Fig. 3.11 A). In each assay plate, DMSO was used as the negative control (low 
signal in mP), whereas blank assay buffer was used in the reaction to function as the 
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positive control (high signal in mP). The average Z′ factor was 0.73 when both intra- and 
interplate variations were considered. The hit rate was 0.31% for compounds (10 μM) 
exhibiting more than 3 standard deviations from the mean of the plate in the fluorescence 
polarization reading. The correlation coefficient for the parallel runs was 0.98 (Fig. 3.11 
B), further demonstrating that the assay exhibits excellent characteristics for a high-
throughput screen. 
Figure 3.11. Pilot screen of the LOPAC1280 library. (A) Scatter plot of fluorescence 
polarization changes after incubation of ARF1 and ARFGAP1 with individual 
compounds of the LOPAC1280 collection. (B) The correlation coefficient for two 
parallel screens of the LO PAC 1280 library was 0.98. 
3.2.5 Screen of 5, 000 kinase inhibitors  To further demonstrate the utility of this 
assay to identify ARFGAP regulators in the 384-well format, we screened the collection 
of 5, 000 kinase inhibitors at CICBDD with the help of Drs William Janzen and Emily 
Hull-Ryde (Fig 3.12). The screen was carried out in singlet. In each assay plate, DMSO 
was used as the negative control (low signal in mP), whereas the assay buffer instead of 
the GAP domain of ARFGAP1 was used in the reaction to function as the positive 
control (high signal in mP). The screening results indicated that only two compounds 
showed more than 50% inhibition. If considering a cutoff of 16% inhibition of the GAP 
activity of the GAP domain, we were able to obtain 32 hit compounds. The hit rate is 
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about 0.64%. 12 concentrations of these hit compounds were used for dose-response 
studies which covered just a whole 384 well plate.  
Figure 3.12. Screen of 5, 000 kinase inhibitors. Normalized inhibition of reactions of 
ARF1 and ARFGAP1 with individual compounds of 5, 000 kinase inhibitors. 
To validate hit compounds we started with BM11, which showed potent inhibition 
in both the screens against the Preswick library and LOPAC library. This chemical 
structure is shown in Fig 3.10 B. This molecule showed dose-dependent inhibition in FP 
assays (Fig 3.10 B). In MBA-MD-231 cells, it inhibited GAP activity and led to 
accumulation of ARF-GTP levels (data not shown). However in radio active GTP 
hydrolysis assays this molecule did not inhibit GAP activity (data not shown). In ITC 
assays and SPR assays, this molecule also did not bind to the GAP domain (data not 
shown). We later realize that false positive response of BM11 is due to the spectral 
overlap of BM11 and Alexa 633 in the FP assay. 
Only three hits from the 5, 000 kinase inhibitors showed dose-response curve in 
the follow-up validations (Fig 3.13). We picked these three hits for further 
characterization. However, none of them inhibited GAP activity in radio active GTP 
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hydrolysis assays (Fig 3.14). In ITC binding assays, these hit compounds did not bind to 
GAP domains (data not shown). We concluded that these three compounds are false 
positive hits. We briefly looked into the potential reasons for these false positive results. 
Compound E13 is not soluble when making the 100 μM stock solution for dose-response 
studies. The precipitation still present when further diluted to 1 μM. This precipitation 
could alter the fluorescence signals in the screening assays leading to the apparent 
“inhibition”. The reasons for false inhibition by compounds I3 and L3 remain unclear. 
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Figure 3.13. Chemical structures and IC50 of E13, I3 and L3. The IC50 were measured 
as 1.3 M, 4.1 M and 10.3 M through dose-dependent response experiment. 
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Figure 3.14. Inhibition effecs of E13, I3, L3 and DMSO on GAP activity of ARF-
GTP hydrolysis. 
3.2.6 Preparation ARF1, GAP domain and ASAP1 for screening in the 
molecular screening center at the Scripps Research Institute  To discover ARFGAP 
inhibitors that directly interact with the GAP domain, we are collaborating with the 
Scripps Molecular Screening Center to screen a diverse library of 360,000 compounds. 
The ARFGAPs that will be used in the screen include [1-136]ARFGAP1 and [325-
724]ASAP1. In collaboration with a technician, Mr. Pavan Denduluri, in the lab, we have 
prepared the first batch of 288.7 mg of ARF-GTP protein, 68.4 mg of the GAP domain of 
ARFGAP1 and 60.2 mg of [325-724]ASAP1. Using these purified proteins, the screening 
center has completed the validation of FP assay in 384-and 1536-well formats. 
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3.3 Experimental Section 
3.3.1 Expression and purification of ARF1 and ARFGAPs  Three different 
ARFGAPs including rat ARFGAP1, human ASAP1, and human stromal membrane-
associated GTPase-activating protein 2 (SMAP2), are used in this work. The expression 
constructs for the GAP domain of rat ARFGAP1 (His6-ARFGAP1[1-126])(118), His6-
ASAP1[325-724](163), and GST-SMAP2[1-163]-His6(164) are obtained from Drs. 
Jonathan Goldberg (Memorial Sloan-Kettering Cancer Center), Paul Randazzo (National 
Cancer Institute), and Masanobu Satake (Tohoku University), respectively. The soluble 
ARF1, with the N-terminal 17 amino acid residues deleted, was used as the ARF for the 
assay development. The expression construct was also obtained from Dr. Jonathan 
Goldberg. All the four proteins were expressed and purified according to literature 
protocols.  
3.3.2 Native gel assay  The native gel assay was carried out according to the 
literature protocol(118). Briefly, The purified ARF1 (1.7 mM, 4 μL) was loaded with 
GTP (5 mM, 4 μL) by incubating the protein with GTP in the loading buffer (25 mM 
HEPES, 150 mM NaCl, 1 mM MgCl2, 5 mM EDTA, 2 mM DTT, pH 7.5) at room 
temperature for 40 min. A solution of MgCl2 (2 M) was then added to a final 
concentration of 20 mM. The so-formed ARF-GTP was stored at 4 
o
C prior to use. To 
carry out the native gel assay, ARF-GTP (170 M, 1.9 μL) and ARFGAP1 (15 M, 4.3 
μL) were incubated in the assay buffer (25 mM HEPES, 150 mM NaCl, 20 mM MgCl2, 5 
mM EDTA, 2 mM DTT, pH 7.5) for indicated times at room temperature. The mixtures 
were then loaded into GE homogeneous 20% polyacryamide gel (GE Healthcare Life 
 81 
 
Sciences) and the ARF1-GTP was separated from the ARF1-GDP on the gel subjected to 
electrophoresis at 4 
o
C and visualized through Coomassie blue staining. 
3.3.3 Fluorescence polarization assay  A solution of the GAP domain of rat 
ARFGAP1 (5 μM, 4 μL) in the buffer (25 mM HEPES, 150 mM NaCl, 20 mM MgCl2, 5 
mM EDTA, 2 mM DTT, pH 7.5) was added to a 384-well plate that contains ARF1-GTP 
(2.5 μM, 16 μL), which was generated as described in the native gel assay. The reaction 
mixture was incubated at room temperature for varying times. The enzymatic reaction 
was terminated by adding the stop and detection buffer (10 μL, Bellbrook labs, contains 
20 mM HEPES, 40 mM EDTA, 0.02% Brij-35, 4 nM GDP Alexa 633 tracer, and 14 
g/mg GDP antibody). The fluorescence polarization was measured 20 min after adding 
the detection buffer on a BMG labtech PHERAstar plus instrument with an excitation 
wavelength of 590 nm and an emission wavelength of 675 nm. A well that contains free 
tracer (30 μL) was set as 20 mP and used as an internal standard. Each reaction was 
carried out in triplicates and GraphPad Prism 5 was used to analyze the data.  
3.3.4 Enzyme kinetics  [△17]ARF1 (400 μm) is loaded with GTP  in buffer [25 
mM HEPES, pH 7.5, 150 mM NaCl, 1 mM MgCl2, 5 mM EDTA, 2 mM DTT, 2.4 μM 
GTP,  [γ32P] GTP] for 40 min at room temperature. A solution of MgCl2 (2 M) was then 
added to a final concentration of 20 mM. The ARF-GTP solution was then diluted into 
desired concentration for kinetic reactions. The GTP hydrolysis was initiated by adding 
GAP domain of ARFGAP1 to a series of [△17]ARF1 solutions.  
3.3.5 Screening of the Prestwick chemical library  The small molecule 
compounds from the Prestwick chemical library were dissolved in DMSO to form a stock 
solution with the concentration of each compound at 1 mM. The stock solution was 
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further diluted with the ARFGAP assay buffer to generate the working solution with the 
concentration of each compound at 100 M. To carry out the screen, the working 
solution of compounds (2 L) was added to the GAP domain of rat ARFGAP1 (5 M, 4 
L) in the assay buffer (10 L). The plate was incubated at room temperature for 10 min, 
and then ARF1-GTP (10 M, 4 L) was added to initiate the reaction. After 2 h, the 
enzymatic reaction was stopped by adding the stop and detection buffer (10 μL), and the 
fluorescence polarization was read as above described. Each reaction was carried out in 
triplicates. 
3.3.6 Screening of the LOPAC1280 chemical library  The small-molecule 
compounds from the LOPAC1280 (Sigma-Aldrich) were dissolved in DMSO to form 
stock solutions (1 mM). The stock solutions were further diluted with ARFGAP assay 
buffer to generate working solutions (100 μM). The 384 plate (Corning) used in 
screening of the Prestwick Chemical Library is not adapted into the screening facilities in 
the CICBDD center. To use a low volume 384 well plate (Perkin Elmer) fitted in the 
screening robot, we optimized the concentrations and volumes of the reaction. To carry 
out the screen, working solutions of compounds (2 μL) were added to the GAP domain of 
rat ARFGAP1 (6.7 μM, 3 μL). The plate was incubated at room temperature for 10 min, 
and ARF1-GTP (13.3 μM, 3 μL) was subsequently added to initiate the reaction. After 2 
h, the enzymatic reaction was stopped by adding the stop and detection buffer (8 μL), and 
the fluorescence polarization was read as described above. Each reaction was carried out 
in duplicate. 
 83 
 
3.3.7 Screening of 5, 000 Kinase Inhibitors  The screening of 5, 000 Kinase 
inhibitors were carried out the same way as the screening of LOPAC1280 Chemical 
Library. 
3.3.8 Validation of hit compounds in radio active GTP hydrolysis assays  The 
radioactivity-based GTP hydrolysis assay was carried out similarly as described in 
Chapter Two. 
3.3.9 ITC binding assays  Microcalorimetric measurements of QS11 and hits 
binding to the GAP domain of ARFGAP1 were performed on a VP-ITC isothermal 
titration calorimeter (Microcal, Northampton, MA, USA). QS11 (10 μM) dissolved in 25 
mM HEPES, pH 7.5 and 150 mM NaCl was filled into the microcalorimetric cell 
(volume, 1.3 mL) and titrated with 30 X 8 μL injections of 200 μM the GAP domain at 
240 s intervals from a 250 mL injection syringe at room temperature. The solutions were 
thoroughly degassed before the titration and the cell contents were stirred constantly at 
300 rpm. As a control, the GAP domain was also titrated into buffer under the same 
conditions and the heat of dilution was subtracted. The heat that was generated from each 
injection was plotted versus time. and analyzed with the MicroCAL Origin software.  
3.3.10 SPR Analysis  The SPR analysis was carried out as described in Chapter 
Two. 
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3.4 Conclusion 
In summary, we have developed a robust high-throughput screen that will be 
useful to identify small molecule ARFGAP modulators. Compared to traditional 
ARFGAP assays based on radiolabeled GTP analogs, this methodology uses fluorescence 
polarization to monitor GTP hydrolysis of ARF-GTP and handling radioactive, hazardous 
waste is avoided. Nonetheless, reliance on fluorescence polarization is not without 
potential limitations. For example, compounds that directly interfere with fluorescence 
polarization could be misinterpreted as potential leads. Perhaps more relevant, any 
compound that affected the affinity of (1) the antibody to bind the fluorescent tracer or (2) 
the ARF GTPase to bind guanine nucleotides might also be misinterpreted as a potential 
modulator. Consequently, secondary assays such as measuring the direct binding of 
compounds with ARFGAPs have to be developed to confirm the ARFGAP inhibition in 
the fluorescence polarization assay. In conclusion, this newly developed assay is ideal for 
measuring ARFGAP activity in large numbers of samples and should be particularly 
useful for the HTS of compound libraries to identify small-molecule modulators of 
ARFGAPs.  
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3.5 Future Plan 
We are currently collaborating with the Scripps Molecular Screening Center to 
discover small molecule inhibitors of both ARFGAP1 and ASAP1. Once the hits are 
discovered from the screen, single dose of these new hit compounds will be first 
confirmed in [γ32P] GTP hydrolysis assays. Those hit compounds showing potent 
inhibition (>50% inhibition) compared to the DMSO control will be then verified in 
dose-response studies in [γ32P] GTP hydrolysis assays. The confirmed hit compounds 
will be further evaluated in ITC and SPR binding assays. The most potent hit compounds 
will be tested in cell-based ARF-GTP pull down experiments. The best hit compounds 
will be then optimized through SAR studies and tested for selectivity among ARFGAPs. 
The effects of the inhibitors on ARFGAP-related cellular processes, such as cell 
migration, will also be tested.  
ARFGAPs require membrane components to function efficiently in the 
endogenous system. In in vitro environment, various lipids have been used to mimic the 
membrane structures. It would be interesting to investigate whether the ARFGAP activity 
in the presence of liposome can be measured in this FP assay. We will first  test whether 
the assay can be used to efficiently measure the hydrolysis of GTP that bounds to the 
myristoylated ARF1 in the presence of full-length ARFGAP1 and phosphatidylcholine. 
Once validated, more complex lipid conditions would be used to optimize the GAP 
activity of ARFGAP1 and other ARFGAPs.  
  
  
 
 
 
Chapter 4. 
Generation of Novel Myristoylated ARFs by Metabolic Interference 
This work is a collaboration project with Drs. Zhiquan Song and Yanbao Yu. Dr. 
Song synthesized six myristic acid analogs and expressed and purified four myristoylated 
ARF1. He also demonstrated that the incorporation of a keto functional group would 
enable its labeling by a fluorescent dye. I expressed and purified the first four 
myristoylated ARF1s, and characterized the modified ARF1s by measuring their 
capacities of GTP-loading and hydrolysis catalyzed by ARFGAP1. The mass spectra for 
the modified ARF1s were obtained by Dr. Yanbao Yu.  
 
4.1 Introduction 
Myristoylation and palmitoylation of proteins play important roles including 
localizing proteins to various cellular membranes and sub-membrane domains and 
facilitating protein-protein interactions.(165) Myristoylation is the irreversible covalent 
attachment of myristic acid to an N-terminal glycine in a target protein, catalyzed by the 
enzyme N-myristoyl transferase (NMT).(166) Although myristoylation is an irreversible 
modification, the duration of myristoylated proteins on membranes can be dynamically 
regulated by ligand binding.(167-171) For examples, GTP binding to ARF could induce 
the conformation change of ARF and allow the exposure of the myristol motif and lead to 
membrane localization of ARF(169). 
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The regulation of NMT activity is not well understood and it was shown that 
endogenous inhibitors NMT inhibitor protein 71 (NIP71) regulate NMT activity in in 
vitro NMT assays.(172-174) In addition, the glycolytic enzyme enolase is able to inhibit 
N-myristoylation in vitro.(175) Phosphorylation of NMT1 also regulates the activity of 
the enzyme and affects the efficiency.(176,177) For example, the N-terminal domain of 
NMT1 interacts with the Lyn tyrosine kinase in a phosphorylation-dependant 
manner.(176) However, how phosphorylation crosstalks with myristoylation has not been 
well understood.  
Myristoylation is implicated in many diseases. Increased expression of NMT has 
been found in colon, gallbladder, breast and brain cancers.(178-181) Inefficient 
myristoylation of the SHOC2 protein has been linked to the development of the Noonan-
like syndrome with loose anagen hair in twenty-five patients.(182) In addition, some 
bacterial strains inject bacterial proteins into the cytoplasm of the host cell.(183-185) 
Myristoylation of these bacterial proteins by host cells would facilitate the bacteria 
virulence.(184,185) Consequently, targeting these proteins may present an effective 
strategy to prevent bacteria infection . 
Most studies of myristoylated proteins relied on the [
3
H]-myristic acid.(186) 
However, the method of using radioactive [
3
H]-myristic acid has low sensitivity and the 
detection takes one to three months. To shorten the experimental time, [
125
I]-
iodomyristate has also been synthesized and utilized so that the experiment can be 
finished within days.(187,188) However, the handling of the hazardous high-energy 
125
I 
radioisotope has caused health concerns. In order to avoid the use of radioactive materials, 
several chemical bio-orthogonal tools have been developed.(186,189,190) These tools 
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use “click chemistry” to identify novel myristoylated proteins in faster and more sensitive 
manners. However, these tools require preparations of both azide and alkyne reagents and 
they are used for affinity purification and identification of lipid modified proteins. 
We are interested in developing novel and convenient methods to identify and 
charaterize both myristoylated proteins and their interacting proteins through metabolic 
interference. The small GTPase ARF1 is used as a model system because it is 
myristoyalted under endogenous conditions and we have substantial experience in 
characterizing ARFs and ARFGAPs. 
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4.2 Results and Discussion 
4.2.1 Modified myristic acid  To explore whether modified myristic acids could 
serve as chemical probes for protein myristoylation, we synthesized a series of myristic 
acid analogs (Table 4.1). The modifications are designed for specific, potential functional  
applications. For example, the keto modification could be used for labeling proteins 
modified by this lipid with hydrazine-containing fluorophore. Proteins modified with the 
three perfluorinated lipids can be digested by proteases and the resulting peptides 
conjugated with perfluorinated group could be enriched by fluorous affinity resin for 
detection of low abundant myristoylation proteins through MS analysis. Furthermore, the 
selenium (Se)-modified lipid could be cleaved selectively by oxidation, thus the activity 
and localization of the corresponding ARF1 could be regulated. Finally, the diazirine-
containing myristic acid analog will generate reactive carbine upon light illumination, 
thus providing a new method to identify interacting proteins of myristoylated proteins. 
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Table 4.1. Chemical structures of designed myristic acids.  
Myristoylation of recombinant ARF1 is achieved by coexpression of ARF1 with 
N-myristoyltransferase (NMT) in E. coli because bacteria lack transferase activity. The 
colonies with full-length ARF1 were obtained from Dr. Paul Randazzo as described in 
Chapter Two. NMT catalyzes the transfer of exogenous myristic acids to the glycine 
residue at the N-terminal of ARF1. BL21 (DE3) bacteria were cultured in the presence of 
different myristic acid analogs before IPTG induction. The myristoylated ARF1 were 
then purified according to the literature protocols.(140) 
4.2.2 Characterization of novel ARFs with modified myristic acids  To 
confirm that the modified myristic acids were successfully incorporated into ARF1, we 
first analyzed the proteins by mass spectrometry. A representative mass spectrum for 
keto-ARF1 was shown in Fig. 4.1. To further confirm that the modification is at the right 
position, both the unmodified and keto-modified myristoylated ARF1 proteins were 
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digested by trypsin and the resulting peptides were analyzed by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) (Fig 4.2). The N-terminal peptide 
GNIFANLFK indicated that a keto group is specifically labeled on the glycine at the N-
terminus of the ARF1 (Fig 4.2). 
 
Figure 4.1. Mass spectra of full length Keto-ARF1.  
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Figure 4.2. Mass spectra of full-length myristoylated ARF1. Unmodified and keto-
modified myristoylated ARF1 proteins were digested by trypsin and the resulting 
peptides were analyzed by liquid chromatography-tandem mass spectrometry (LC-
MS/MS). 
Myristoylation controls ARF functions in membrane binding, vesicle coat protein 
recruitment, nucleotide exchange, interactions with guanine nucleotide exchange factors 
and interactions with PLD. Therefore, it is important to determine whether these modified 
myristic acids changed the activities of ARF1. Accordingly, we measured the guanine 
nucleotide exchange rate of modified ARF1 proteins and the GTP hydrolysis rate of the 
resulting GTP-bound ARF1 in an intrinsic fluorescence assay. As shown in Fig 4.3, all 
six modified myristoylated ARF1 showed similar guanine nucleotide exchange rate as 
that of the native myristoylated ARF1 indicating that the modifications on myristic acid 
did not affect the interaction between ARF1 and GTP. Furthermore, these nucleotide 
exchange reactions were carried out in the presence of liposome. Given that the 
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interaction between the lipid membrane and ARF increases nucleotide exchange 
rate,(119,191) this result also suggested that the interactions between myristoylated 
ARF1 and membrane are not significantly disrupted by modifications on the myristic acid. 
In addition, five modified myristoylated ARF1 showed similar GTP hydrolysis rate in the 
presence of ARFGAP1 indicating that these five modifications did not affect the 
interactions between ARF1 and ARFGAP1 (Fig 4.4). Interestingly, keto myristoylated 
ARF1 showed a 3-fold faster hydrolysis rate within the linear range of the GTP 
hydrolysis (Fig 4.4). One possible reason is that the keto group forms additional 
hydrogen bonds with ARFGAP1 resulting in a tighter interaction between ARF1 and 
ARFGAP1. Overall, these six myristoylated ARF1 proteins maintain the activities of 
unmodified myristoylated ARF1 in interacting with GTP, ARFGAP and lipid membranes. 
 
Figure 4.3. GTP exchange assays of ARFs. ARF1 was added to a final concentration of 
500 nM in liposome. GTP solution was added to a final concentration of 40 μM. EDTA 
was subsequently added to the final concentration of 2 mM (free Mg
2+
 concentration is 1 
μM) to initiate the GTP loading. 
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Figure 4.4. GTP hydrolysis on ARFs catalyzed by ARFGAP1. GTP hydrolysis was 
initiated by adding ARFGAP1 into the cuvette to reach a final concentration of 50 nM 
and the fluorescence was recorded continuously for 10 min. 
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4.2.3 Fluorophore labeling assays  To demonstrate the potential functional 
applications of modified myristoylated ARF1 proteins, purified keto-myristoylated ARF1 
or native myristoylated ARF1 were incubated with fluorescein-hydrazide. The samples 
were separated by SDS-PAGE and detected with both coomassie blue staining and 
fluorescence scanning (Fig. 4.5). In coomassie blue staining, there are two close proteins 
bands shown in the keto myristoylated ARF treated with fluorescein-hydrazide. 
Compared to the untreated keto myristoylated ARF1, the upper band is likely to be the 
fluorescien-labeled myristoylated ARF1. This result is further confirmed by fluorescence 
scanning. Fluorescien-labeled myristoylated ARF1 is present in the samples with keto 
myristoylated ARF1 treated with fluorescein-hydrazide, making it possible to use  keto 
myristic acid for identification of  known or novel myristoylated proteins in mammalian 
cells. 
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Figure 4.5. Selective fluorescein labeling of purified keto-ARF Purified myris-ARF or 
keto-ARF was dialyzed against phosphate buffered saline (PBS). The protein was either 
incubated with 1 mM fluorescein-hydrazide (Molecular Probe) (pre-dissolved in DMF) or 
DMF in PBS for 16 h at -20 °C, respectively. Excess dyes were removed by dialysis in 
PBS buffer. The samples were then denatured, separated by SDS-PAGE and detected by 
both coomassie blue staining and fluorescent scanning. 
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4.3 Experimental Section 
4.3.1 Expression and purification of modified myristoylated ARFs  The single 
colonies of myristoylated ARF1 that contain NMT are from Dr. Paul Randazzo (National 
Cancer Institute).  In analogy to the expression and purification of myrisoylated ARF1, 
we generated the modified ARF1s.(140) Briefly, a single colony from the transformation 
was cultured for 9 h at 37 °C. This culture was used to inoculate 2 L of pre-warmed 
medium (1:100 dilution of culture) in two 2 L baffled flasks.  The cells were grown at 
37 °C with vigorous agitation till OD600 reaches ~ 0.6, at which time, modified myristic 
acid was added to the culture at a final concentration of 50 μM and the incubation was 
continued for another 20 min. Afterwards, IPTG was added to a final concentration of 1 
mM. The cultures were cooled to 25 °C and agitation was continued at 25 °C for 12-16 h.  
The cells were harvested by centrifugation at 4000x rpm for 20 min (Beckman JA10 rotor, 
5000 rpm), and the pellets were stored at -80 °C.The purification methods of 
myristoylated ARF1 are similar to the ones described in Chapter 2. 
The concentration of purified myristoylated ARF1 was determined by a dye 
reagent (Bio-Rad) at UV absorbance at 595 nm. The typical yield of myristoylated ARF1 
is 1 mg from 2 L cell culture. 
4.3.2 GTP loading and GTP hydrolysis in intrinsic fluorescence assay  
Liposome was prepared in a similar way as described in Chapter Two. GTP exchange 
reaction and GAP-catalyzed GTP hydrolysis were monitored in a cuvette containing 
buffer (300 μL) (50 mM Hepes pH 7.2, 120 mM KAc, 1 mM MgCl2, 1 mM DTT) and 
liposome (0.2 mM) in a fluorometer. Tryptophan fluorescence of ARF1 was measured at 
the emission wavelength of 340 nm (bandwidth 14 nm) and the fluorophore was excited 
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at 297.5 nm (bandwidth 3 nm). The basal fluorescence was recorded for 5 min before 
ARF1 was added to a final concentration of 500 nM. After 5 min,  GTP solution was 
added to a final concentration of 40 μM and fluorescence was recorded for another 5 min. 
EDTA was subsequently added to the final concentration of 2 mM (free Mg
2+
 
concentration is 1 μM) to initiate the GTP loading and the fluorescence was recorded for 
10 min. The GTP loading was stopped by adding MgCl2 solution to a final concentration 
of 3 mM and the fluorescence was recorded for 10 min. GTP hydrolysis was initiated by 
adding ARFGAP1 to the cuvette to a final concentration of 50 nM and the fluorescence 
was recorded for 30 min. The fluorescence value was normalized by subtraction of the 
basal fluorescence value from buffer and liposome. In the GTP loading experiment, the 
fluorescence of different ARF-GDP was normazlied as 1.0 after subtractions of buffer 
and liposome. In the GTP hydrolysis experiment, the relative fluorescence of different 
ARF1-GTP was set as 1.0.  
4.3.3 In Vitro fluorescence labeling  Purified myris-ARF1 or keto-ARF1 was 
dialyzed against phosphate buffered saline (PBS) overnight (3 x 2 L) at -20 
o
C. The 
protein was either incubated with 1 mM fluorescein-hydrazide (Molecular Probe) (pre-
dissolved in DMF) or DMF in PBS for 16 h at -20 °C, respectively. Excess dyes were 
removed by dialysis in PBS buffer. The samples were then denatured, separated by SDS-
PAGE and detected by both coomassie blue staining and fluorescent scanning with a 
Typhoon 9400 scanner (GE Healthcare).  
4.3.4 Sample preparation for mass spectra  Purified ARF proteins (1 mg/ml) 
were dialyzed in H2O for 8 h at room temperature. The samples were then injected into 
LTQ-Orbitrap XL mass spectrometer for LC-MS analysis. 
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4.4 Conclusion 
New chemical tools are needed to help us better understand protein myristoylation. 
Here, we describe the strategy of generating novel myristic acid analogs which can be 
efficiently incorporated into ARF1. These modified myristoylated ARF1 proteins 
maintain functions of endogenous myristoylated ARF1 such as nucleotide exchange and 
catalysis of GTP hydrolysis. More importantly, the ARF proteins gain novel functions 
through these designed modifications. We are exploring different functions of these 
modified myristoylated proteins. 
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4.5 Future Plan 
The purified keto-ARF1 are efficiently labeled with a fluorescent dye, raising the 
question whether the proteins in live cells can be modified and labeled. We will explore 
different conditions to feed cultured mammalian cells with keto-modified myristic acid 
derivative and label the cell lysate with fluorescent dye. The myristoylated proteins in the 
cells can thus be identified. Once validated, this method could be further extended to 
explore the dynamic myristoylation of proteins under various extracellular stimulations. 
For perfluoroalkyl-modified ARF1 proteins, we will explore conditions that can enrich 
and detect fluorous peptides from the digested fluorous-ARF1 through fluorous solid 
phase extraction followed by MS analysis. Such enrichment of a subset of peptides is 
essential to identify low-abundant proteins. Regarding the Se-ARF1, we will continue to  
search for a mild oxidation reagent that could cleave the Se-C bond without disrupting 
the structure of Se-ARF1. We are also interested in demonstrating the novel functions of 
diazo-ARF1. It will be interesting to see whether this novel protein can be used to 
identify ARF1-interacting proteins through light-induced crosslinking. 
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Appendix 
 
Appendix A 
1
H NMR (CDCl3) of B3C4 in as an example of QS11 analogs 
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Appendix B Mass spectrum of of B3C4 as an example of QS11 analogs 
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